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ABSTRACT 
Current synthetic alternatives to autologous grafts have often failed in small 
diameter applications (<6 mm) due to their thrombogenicity and compliance mismatch 
of native vasculature.  No known synthetic material is capable of providing a non-
thrombogenic inner layer that promotes endothelial cell (EC) interactions while also 
providing sufficient compliance and burst pressure for long term success in vivo. We 
have developed a multilayer design with an inner thromboresistant poly(ethylene glycol) 
(PEG) hydrogel based on Scl2-2 proteins designed to promote rapid in situ 
endothelialization. The bioactive component is reinforced with an electrospun 
segmented polyurethane (SPU) layer with tunable mechanical properties to withstand 
physiological loading conditions. The modulating of electrospun parameters to influence 
graft architecture coupled with the tunability of SPU mechanical performance is 
expected to give rise to improved graft biomechanical properties. Unfortunately, this 
advantage was found to be limited to only one property at a time. To this end, we have 
developed a novel semi-IPN approach to expand the range of possible graft compliance 
and burst pressures in order to simultaneously achieve biomechanical properties that 
exceed autologous veins. 
In addition to matching biomechanical properties, probability of long term 
success is also dependent on the grafts retention of perfomance despite cell-mediated 
attack. Typically, in the case poly(ether urethanes) (PEUs) and poly(carbonate 
urethanes) (PCUs), oxidative stability is the primary focus in the development of 
biostable SPUs. We have characterized the biostability of several commercially available 
 iii 
 
polyurethanes while simultaneously evaluating the predictive capabilities of two main in 
vitro test methods to optimize our graft’s design. 
Despite ensured long term performance through optimizing biostability, a 
permanent scaffold prevents vasoactivity, a key function of vasculature.  We have taken 
a tissue engineering approach to restorate vasoactivity by evaluating a novel aromatic 
biodegradable poly(ester urethane) (PEsU) for the reinforcing layer of a tissue 
engineering vascular graft (TEVG). This PEsU was expected to degrade into safe 
byproducts given its design based on glycolic acid and ethylene glycol. Following 
characterization, the PEsU was determined to be a strong potential reinforcing layer of a 
potential TEVG design. 
In summary, we have improved small diameter grafts through a multilayer design 
approach. Our graft demonstrated favorable initial fabrication feasibility, promising in 
vivo testing, biomechanical properties exceeding autologous veins, and strong oxidative 
stability. Overall, we have optimized the reinforcing layer through improvement of 
biomechanical properties via modulated material chemistry, optimized biostability, and 
identification of a biodegradable component expected to allow for restored vasoactivity. 
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PBS Phosphate buffered saline 
 
PCL Poly(ε-caprolactone) 
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PCU Poly(carbonate urethane) 
 
PDI Polydispersity index 
 
PDMS Polydimethylsiloxane 
 
PEG Poly(ethylene glycol) 
 
PEGDA Poly(ethylene glycol)-diacrylate 
 
PEsU Poly(ester urethane) 
 
PEU Poly(ether urethane) 
 
PEUU Poly(ether urethane urea) 
 
PET Poly(ethylene terephthalate) 
 
PMN Polymorphonuclear leukocyte 
 
PPO Poly(propylene oxide) 
 
PTFE Polytetrafluoroethylene 
 
ROI Reactive oxygen intermediate 
 
SEM Scanning electron microscopy 
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TEVG Tissue engineering vascular graft 
 
Tg Glass transition temperature 
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CHAPTER I  
INTRODUCTION 
 
1.1 Coronary Artery Disease 
Coronary artery disease (CAD) accounts for close to the majority of all 
cardiovascular disease related deaths in the United States
1
 with annual costs exceeding 
close to $150 billion.
2
 In addition, CAD is estimated to become the leading cause of 
death in the world by 2020.
3
 Patients experience CAD as a result of atherosclerosis, a 
multifocal inflammatory buildup of low density lipoproteins (LDLs) which form fatty 
streaks, Figure 1.1. Depending on physiological location, LDL buildup can cause 
localized turbulent flow patterns within the artery resulting in tissue injury with 
subsequent monocyte recruitment and macrophage differentiation.
4
 Macrophages 
oxidize the LDLs on the vessel wall and encompass them along with smooth muscle 
cells (SMCs) to form foam cells. The foam cells then build up behind the endothelial 
wall by combining with collagen matrix synthesized by SMCs.  The atheroma continues 
to expand as a result and over time can produce localized turbulent flow within the 
vessel damaging the endothelial layer.  The body recognizes the site of injury and sends 
platelets which aggregate and eventually lead to occlusion. In addition, atheromas could 
potentially rupture causing the contents to form an occlusive thrombus
5
 or flow 
downstream and occlude smaller diameter vessels. In the most severe of these cases, 
invasive surgical approaches including coronary artery bypass or arterial replacement 
procedures are used prior to atheroma rupture. 
 2 
 
 
Figure 1.1. Atheroma formation. Starting at infancy, fatty streak forms which progresses 
into additional complex plaque formation covered by a fibrous cap. The cap eventually 
weakens and ruptures allowing for an occlusive thrombus to aggregate or flow 
downstream (Figure taken from Reference 4) 
 
 
Autologous grafts harvested from the saphenous vein or internal mammary artery 
have been the gold standard but are not available in approximately 20% of patients due 
to disease, trauma, or anatomic abnormalities.
6,7
 Allografts derived from cadaveric 
saphenous veins are a more readily available alternative to autologous grafts but are 
often met with complications typically involving damage to the intimal layer due to pre-
implantation processing and immunological risks.
8-12
 Synthetic grafts such as the Dacron 
graft, composed of poly(ethylene terephthalate) (PET), and the Gore-Tex graft, made of 
expanded polytetrafluoroethylene (e-PTFE) have also been used as alternatives to 
autologous grafts. These options have been successful in large diameter applications, but 
in smaller applications (d < 6 mm), grafts typically occlude due to thrombosis and 
intimal hyperplasia derived from compliance mismatch at the anastomosis site. Large 
diameter grafts have been successful in particular due to antithrombotic treatments. The 
 3 
 
same treatments have been unsuccessful in preventing occlusion in small grafts leading 
scientists to believe compliance mismatch is the dominant cause of occlusive failure.  
Studies have shown a direct correlation between compliance and long-term patency 
of vascular grafts ranging from saphenous veins to synthetic grafts,
13
 Figure 1.2. In an 
end-to-end anastomosis model, the difference in stiffness causes a convergence of flow 
at the proximal end and a divergence of flow at the distal end of the graft due to dilation. 
The discontinuity of flow results in stagnation points at the distal end forming eddies, 
which increase shear stresses on the walls of the native tissue. These stresses can often 
damage the endothelial layer and induce platelet aggregation at the injury site which 
blocks flow.
14
 Alternatively, the platelets may migrate downstream also resulting in graft 
occlusion. The stagnation points can provide a lack of blood flow in localized areas 
distal to the anastomosis. As a result the wall shear stress or rate is reduced causing the 
artery to reduce its inner diameter to increase the applied forces via intimal hyperplasia. 
The inner diameter of the artery is ultimately expected to decrease until occlusion.
15,16
 
Alternatively, the increased platelet residential time allows for prolonged release of 
growth factors from the platelets inducing further smooth muscle cell proliferation.
16
 
Finally, intimal hyperplasia can arise from the stress concentrations applied along the 
suture line of the distal anastomosis as a result of the artery increasing the proliferation 
of smooth muscle cells to accommodate the enhanced radial stresses applied.
17
 
 4 
 
 
Figure 1.2. Direct correlation of graft compliance and 5 year patency rates. 
(Figure taken from Reference 13) 
 
1.2 Vascular Graft Materials 
Materials developed for vascular grafts can be categorized into two main groups: 
natural and synthetic materials. The former typically involves either collagen or a 
combination of collagen and gelatin. Scaffolds have been fabricated before by dissolving 
collagen and mixing in smooth muscle cells before combining it with a Dacron
®
 graft 
and an additional collagen-fibroblast solution.  Endothelial cells were then seeded on the 
inside to form a non-thrombogenic intimal layer. While the approach showed promise in 
fabricating vascular grafts ex vivo the resultant grafts had poor burst pressure due to lack 
of SMC alignment.
18
 SMCs were later aligned by culturing them under stressed 
conditions though mechanical properties were still well below that of an autologous 
artery.
19-22
 Electrospun collagen and elastin fibers have been used to form composite 
grafts/cell hybrids. Collagen I was electrospun and showed a three dimensional 
architecture for an ideal tissue engineered scaffold,
23
 though burst pressure and 
 5 
 
compliance values were not reported. In addition, the feasibility of the use of electrospun 
collagen I in blood contacting applications has yet to be determined.
24
 Ratios of collagen 
and elastin have been electrospun in a blend to better mimic each layer of the lumen 
separately.
25
 The challenge of matching native vessel structure and mechanical 
properties still exists with no current studies addressing the issue using purely natural 
materials.
26
 
Synthetic materials are advantageous over natural materials in that burst pressure has 
been achieved in traditional synthetic grafts as well as the risk of batch-to-batch 
variability is greatly reduced. Woven or knitted Dacron
®
 grafts were the first to be 
fabricated with various porosities to optimize the rate of cellular ingrowth however pre-
clotting procedures using fibrin layers were required to prevent leakage. Numerous 
coatings have been applied to Dacron grafts to ultimately improve its success rate 
including: fluoropolymer for thromboresistance,
27
 collagen and heparin for tissue 
incorporation without clotting,
28
 fibrin for cultivation of endothelial cells,
29
 silicone 
elastomer to make more bioinert,
30
 and gelatin to improve neointima formation.
31
 While 
these techniques have shown improvement in acute tissue ingrowth, scientists have 
determined the main cause of failure in the long term (>6 months) to be compliance. 
Expanded-polytetrafluoroethylene (e-PTFE) is the preferred graft of the two 
traditional synthetic grafts. E-PTFE grafts mechanically are less stiff (3-6 MPa
32,33
) than 
Dacron grafts (12 MPa) in the circumferential direction but still have much greater 
stiffness than native arteries and veins (600, 900 kPa respectively). The mechanical 
difference of both synthetic options compared to autologous grafts is further highlighted 
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with their results in patency.  While e-PTFE and Dacron
®
 graft patency rates were found 
to be statistically similar after 5 years, the patency of autologous grafts was still far 
greater.
26
 For endothelialization, increased porosity going from 30-90 µm in a canine
34
 
model was found to be effective but a smaller increase of 30-60 µm showed no 
difference in canines
35
 or humans.
36
 Furthermore, e-PTFE grafts are believed to be more 
thromboresistant than other vascular grafts due to the electronegativity of the material.  
This feature has been further enhanced with carbon coating or impregnation which was 
found to decrease platelet adhesion even more.
35,37-39
 Finally, fibrin glue incorporated 
with growth factors has been utilized to increase thromboresistance.
40,41
 Though these 
techniques have been very successful in preventing acute occlusion by combating 
thrombosis, ultimately patency was not found to improve with any of them again leaving 
scientists to believe compliance is the key cause. Thus, a new material is needed that can 
address the issues with mechanical properties so that compliance does not remain an 
issue. 
 
1.3 Polyurethane Grafts with Improved Compliance 
Synthetic grafts can occlude via numerous pathways related to compliance mismatch 
between native tissue and the graft at the anastomosis; therefore it is important to 
develop vascular grafts with better compliance despite the inverse relationship with burst 
pressure. Segmented polyurethanes (SPUs) have been used frequently in biomedical 
devices since the 1960s
42
 due to their established mechanical properties, high tunability, 
and biocompatibility.
43,44
 This subclass of polyurethanes consists of a soft segment, 
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typically a high molecular weight polyol, and hard segment composed of a low 
molecular weight aromatic or aliphatic isocyanate compound and chain extender with 
hydroxyl or amine end groups.
45,46
 
SPUs provide a favorable option for meeting requisite mechanical properties, 
including compliance,
47
 as their tunability allows for excellent mechanical strength and 
good fatigue life while also providing the needed flexibility. More importantly, their 
microphase morphology provides the added polymer chain interactions to achieve 
elastomeric mechanical properties superior to traditional graft materials. SPUs are made 
of a hard segment consisting of a low molecular weight isocyanate-terminated molecule 
and an alcohol or amine terminated chain extender. The soft segment is typically made 
of a high molecular weight polyol or polyamine. SPU polymer chains form hard 
domains dispersed within a soft segment matrix as unstrained conditions.
48
 The hard 
segment provides strength and rigidity while the soft segment adds flexibility.  
At initial strains (< 100%) the soft segment matrix chains respond to axial forces by 
stretching parallel to the force direction. Hard segments are then expected to break up at 
approximately 100% strain. Following hard segment breaking, the smaller domains 
orient themselves in the direction of the strain. During this section, also known as the 
rubbery plateau, little to no additional stress is applied to the material. At the onset of 
strain hardening (~200-300%), soft segment crystallization is initialized and there is a 
stronger dependence between soft and hard segment orientation.
48
 The same stress vs. 
strain behavior has been seen in mechanical testing of carotid artery tissue including 
strain hardening.
49
 The key difference between SPU mechanical response and native 
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tissue response lies in the onset of strain hardening.  The deformation point in SPUs’ 
curves is around 200-300% strain but in carotid tissue, the sharp increase in tensile stress 
is seen as early as 100%.
49
 Thus, inducing an earlier strain hardening effect on SPUs 
could provide could provide the opportunity to meet the compliance of native tissue 
without sacrificing burst pressure.  
Silicones have also long been used in medical devices because of their known 
biostability, anti-adhesive properties and, most importantly, low modulus due to low 
glass transition temperature.
50-53
 Applications of silicones have been limited to devices 
not requiring useful engineering properties because the elastomers have been generalized 
as relatively weak when it comes to load bearing applications.
54
 Tensile strength has 
been enhanced previously by covalently incorporating stronger chemical groups within 
the backbone
55
 or polar side groups.
56,57
 Mechanical fatigue life has also been improved 
with the inclusion of a urethane component in the silicone backbone for use in a 
commercially available material, Avcothane 51.
58
 It is evident that these approaches to 
increasing the tensile strength and fatigue life of silicone elastomers are effective. 
However, the mechanical properties of the additive/copolymer component are often 
compromised as a result.  Thus a new approach is needed that allows the designer to 
retain the characteristic properties of each component in a combination without 
sacrificing the other. 
Interpenetrating polymer networks (IPNs) are distinguishable from most blends or 
copolymers in that they can provide the ability to retain the major characteristics of one 
network component without sacrificing any properties of the other. Briefly, traditional 
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IPNs incorporate two or more covalently crosslinked polymer networks that are not 
covalently bonded together but cannot be separated without breaking chemical bonds. 
Semi-interpenetrating polymer networks (semi-IPNs) differ from standard IPNs in that 
the components can potentially be separated without the need for breaking covalent 
bonds. SPUs have often been used as one of the components in semi-IPNs for various 
biomedical applications
59-64
 to contribute to the overall mechanical properties of the 
network. These applications can include wound dressings,
65-67
 uretral
68
 and blood 
contacting materials.
69-71
 Poly(dimethyl siloxane) (PDMS)-based materials have also 
been utilized as components in both IPNs,
72-76
 and semi-IPNs
77,78
 for various biomedical 
applications. Finally, a scarce amount of SPU/PDMS
79-81
 semi-IPNs have been 
synthesized though, to the best of our knowledge, none have focused on optimizing 
compliance and burst pressure vascular grafts. Based on the previous work presented, 
semi-IPNs are a strong approach in achieving overall favorable in vivo performances, but 
the strict materials approach only accounts for a portion of the control over graft 
biomechanical properties.  Exploration into the fabrication of grafts has the potential for 
even further enhancement vascular graft performance through control over graft 
architecture. 
  
1.4 Fabrication of Polyurethane Grafts 
The growing prevalence of polyurethanes in medical devices is due to the 
previously reviewed performance properties and tunability, therefore it should be of no 
surprise that this class of materials has been frequently explored in prior vascular graft 
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designs. Early polyurethane graft designs utilized a phase separation technique
82
 which 
typically earned a compliant description however burst strength was most likely 
insufficient given the need for reinforcing materials such as polyesters
83
 or silicones.
84
 
Thus, new designs still need to address the compliance match requirement but also look 
to retain burst pressure eliminating the need for a reinforcing layer. 
Electrospinning has recently gained significant attention in the design of various 
biomedical devices because it provides a facile and tunable method to produce porous 
scaffolds and devices, Table 1.1. In addition, specific electrospun fibers have previously 
been demonstrated to retain strength well beyond fibers produced via alternative 
methods but with similar architectures;
85
 however, their porous morphology still allows 
for a highly compliant material.
86
 Briefly, a polymer is dissolved in a conductive solvent 
and dispensed through a charged needle positioned at a specific distance from a 
grounded/oppositely charged collector at a controlled rate. The electrical force applied 
on the polymer solution stretches the droplet emerging from the needle until a critical 
voltage causes a jet to spring towards the collector.
87
  The solution jet experiences 
whipping paths and splaying prior to reaching the target which dries any remaining 
solvent leaving fibers with diameters on the order of nanometers to low microns. 
 
 
Table 1.1. Electrospun polyurethane medical devices 
Electrospun Polyurethane Medical Devices 
General Tissue Engineering (TE)
88-118
 Wound Dressing
119-127
 
Musculoskeletal TE
128-134
 Drug Delivery
135-139
 
Neurological TE
140,141
 Additional Devices
142-151
 
Cardiovascular TE
136,152-180
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A typical electrospinning setup allows the user to manipulate several variables to 
tailor the resulting fiber mesh to meet the specific needs of their application.  Fiber 
alignment and patterning has been of interest especially in vascular grafts because 
control over fiber orientation and morphology can have an added effect on the 
construct’s overall mechanical properties better mimicking of graft properties.  More 
common attempts at controlling fiber alignment include setups that replace a stationary 
target with a rotating mandrel to help spool the fibers forcing them to align in the 
direction of rotation.
181-186
 While the technique is highly proficient in providing the small 
diameter tubular overall construct needed for synthetic vascular grafts, tissue anisotropy 
is still not fully captured with the rotating mandrel setup alone.  
Recently, it was found that polyurethanes could be patterned on the micro scale 
using substrates fabricated from soft lithography.
95
 When electrospun on the PDMS 
substrates with specific grid patterns, the removed PEsU fibers were found to mimic the 
same grid pattern. The fibers showed a bimodal distribution of diameter with smaller 
fibers inside the grids and larger fused ones along the raised pattern features. 
Commercially available BioSpan
®
, a poly(ether urethane urea) (PEUU), was also 
electrospun on the same grid patterns and showed no fusing or orientation along the 
topography features. When both SPUs were electrospun on flat PDMS substrates both 
sets of fibers had randomized fiber orientations though the PEsU fibers still showed a 
bimodal diameter distribution with the same fiber fusion effect. The study concluded that 
the ester linkages within the PEsU fibers showed greater sensitivity to changes in the 
electric field due to surface topography differences because of their greater dipole 
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moments
187
 than the ether groups in PEUU. In addition, the fibers were attracted to each 
other as the polar carbonyl groups of the linkage are presumed to align themselves in the 
direction of the electric field
188
 leaving oppositely charged ends facing incoming fibers. 
With this new phenomena on select electrospun polyurethane chemistries, the unique 
patterned and bimodal distribution of fiber morphologies is expected to give a more 
complex improved control over graft biomechanical properties. 
Though fabrication of the electrospun graft, coupled with modulation of material 
chemistry is a promising approach for achieving both compliance and burst pressure 
simultaneously, it does not guarantee the success of the graft in the long term.  The 
mechanical performance of the graft must be maintained. Thus a key component not yet 
addressed in this review important in retaining graft properties is determining the 
biostability of the vascular graft. 
 
1.5 Understanding Polyurethane Biostability for Retention of Graft Properties 
Maintaining biostability has been a functional requirement in designing 
traditional vascular grafts due to the expected exposure to water and macrophage 
mediated biodegradation.
189
 Following implantation, the body’s inflammatory response 
begins with an initial appearance by polymorphonuclear leukocytes (PMNs), a 
neutrophil, but are known to disappear within 24-48 hours.
190
 Monocytes then migrate to 
the site and differentiate into macrophages which eventually fuse together to form 
foreign body giant cells (FBGCs), which create a closed compartment where they secrete 
reactive oxygen intermediates, acids, and enzymes.
190-192
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Before the effects of the cell-biomaterial interactions can be studied, it is 
important to understand that the general degradation process typically followed by 
polymers. The degradation medium (i.e., water, salts, peroxides, enzymes) is first 
adsorbed on the polymer surface. Next, the medium diffuses into the bulk of the polymer 
and begins to chemically react with the unstable or labile bonds in the polymer chains. 
The reactions often result in polymer chain cleavage reducing the polymer chain length 
or molecular weight. When the length is reduced enough the degradation medium is able 
to dissolve portions of the degraded polymer and transport them out of the bulk 
polymer.
46
 
The first generation of polyurethanes, poly(ester urethanes) (PEsUs), were 
known to degrade quickly in the body due to their hydrolytically labile aliphatic soft 
segments.
193,194
 Water molecules infiltrate the polymer matrix and attack the bond 
connecting the backbone oxygen and carbon of the carbonyl within the ester linkage 
leaving alcohol and carboxylic acid end groups,
46
 Figure 1.3.  
 
Figure 1.3. Hydrolysis reaction of general segmented PEsU. 
The degradation behaviors of polyurethanes are most often characterized with in 
vitro degradation studies.
195-210
 Depending on the hydrophilicity of the polyurethane in 
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question, degradation behavior can fall into two distinct categories: bulk 
degradation
202,209
, and surface erosion.
202,211
 Polymers known to be highly hydrophilic 
will exhibit a diffusion rate that is faster than the rate of hydrolytic degradation allowing 
water molecules to penetrate before cleaving the ester linkages.  Evidence of degradation 
will be spread throughout the bulk of the polymer as a result. This behavior is commonly 
referred to as bulk degradation. For more hydrophobic polymers, the opposite is true 
where the rate of hydrolysis is faster than that of diffusion leaving degradation evidence 
only on the surface of the polymer. These materials are undergoing surface erosion. 
Enzymatic hydrolytic degradation is a more specific form of hydrolysis than the 
general reaction because it is dependent on location of the implant as well as ability of 
the enzyme to be adsorbed, Table 1.2.
212
 Following restructuring of the polymer for 
adsorption and desorption, the adsorbed enzyme reacts with and cleaves labile bonds 
before releasing them into the solution.
212,213
 Unlike non-specific hydrolysis, which can 
undergo surface erosion or bulk degradation depending on reactivity and diffusion 
variables, enzymatic degradation is only limited to the surface of the material.  Enzymes 
typically have molecular sizes that are significantly larger than water molecules which 
limit their diffusion. 
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Table 1.2. List of enzymes 
Enzymes  
Chymotrypsin
209,211,214-221
 Urease
222
 
Cholesterol Esterase
223-229
 Papain
218,220,222,230-235
 
Bromelain
218,220,221
 Elastase
110,236-240
 
Protease K
218,219
 Ficin
218,220,221
 
Collagenase
110,224,241-243
 Carboxyl Esterase
244-246
 
Cathepsin B
163,224,247
 Plasmin
248,249
 
Cathepsin C
220
 Lipase
202,250-257
 
 
Poly(ether urethanes) (PEUs) were developed to resist hydrolysis with more 
biostable ether grou0ps in their soft segments. However, research found these soft 
segments to be subject to oxidative degradation including metal ion oxidation and 
environmental stress cracking.
194,258-260
 These included medical devices such as 
pacemaker lead coatings and breast implants. Briefly, an oxygen radical abstracts an α-
methylene from the ether soft segment. The newly formed radical then combines with an 
additional oxygen radical forming a hemiacetal which oxidizes into an ester linkage. The 
ester hydrolyzes forming an acid or aldehyde with or without the presence of another 
oxygen radical. The radical formed during the initiation of oxidation can also combine 
with a nearby formed radical creating a crosslinked network at the surface of the 
material leading to surface embrittlement,
261
 Figure 1.4.  
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Figure 1.4. Ether soft segment oxidative degradation
262
 
 
Oxidative degradation, like enzymatic hydrolysis, is also limited to the surface of the 
polymer but diffusion of the oxygen radicals is not limited due to their size but rather 
their high reactivity.  It is expected that initiation of the oxidation process will occur 
before radicals can infiltrate the polymer matrix, though research has shown the 
possibility of radical chain transfer allowing migration into the material.
263
 
Several attempts have been made to expand on the biostability of PEUs to help also 
resist oxidative degradation. For example, incorporating other known biostable 
components into the SPU chain including polyisobutylenes,
264-270
 and 
polytetrafluoroethylene
270
 has proven to be effective. Silicones, mainly PDMS, have 
been used in biomedical devices because of their elastomeric properties and excellent 
resistance to both hydrolytic and oxidative degradation.
264,271,272
 However, their 
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mechanical properties again are typically insufficient in applications where the device 
has to withstand physiological forces. Others incorporated antioxidants on the surface of 
PEU elastomers to maintain their favorable mechanical properties.  Synthetic 
antioxidants such as Santowhite
®273,274
 and Irganox
®
 are potential candidates
273,274
 as 
well as natural antioxidants such as vitamin E
275,276
 due to its safe release products.
277,278
 
However, these surface treatments are not permanent. 
Recently, SPU synthesis chemists have developed a new generation of polyurethanes 
which incorporate carbonate groups within the soft segment known to be more biostable 
than polyether formulations of the same compositional ratios.
44,279-281
 Poly (carbonate 
urethanes) (PCUs) are expected to undergo oxidative degradation similar to PEUs, 
Figure 1.5., but the lower nucleophilicity of the carbonate group significantly slows 
down the degradation rate.  
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Figure 1.5. Carbonate soft segment oxidative degradation.
262
 
 
Thermoplastic PCU elastomers exhibit the same mechanical properties as PEU 
formulations of similar hard segment compositions; however, PCUs are expected to 
retain most properties due to the electrophilic nature of the soft segment carbonate 
groups. The enhanced biostability demonstrated by accelerated oxidation tests in the 
literature makes PCUs very strong candidates for biostable applications, especially the 
reinforcing layer of a biostable multilayer graft.
194,282-285
 While the multilayer approach 
is promising to provide the requisite properties for successful in vivo deployment, there 
will always be some concern over foreign material remaining in the body.  Furthermore, 
the full function of an artery or vein cannot be replicated without also enabling 
vasoactivity, a highly advantageous feature of autologous grafts. Therefore a tissue 
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engineering approach needs to be employed to not only replace the function of native 
tissue but to ultimately restore it. 
 
1.6 Biodegradable Polyurethanes for Tissue Engineering Vascular Grafts (TEVGs) 
The field of tissue engineering employs a multidisciplinary approach that 
combines the knowledge and technology of cells, biomaterials and bioactive factors to 
fabricate organs.
286
 The overall goal of tissue engineered organs is to not just replace the 
function of natural tissue but to also restore it over time.
287
 Therefore a TE approach to 
fabricating a vascular graft could not only mimic graft biomechanical properties but also 
allow for the restoration of graft vasoactivity. However; the function of vascular tissue is 
greatly dependent on its structure and vice versa,
288
 therefore it is crucial for the tissue 
engineering vascular grafts (TEVGs) to initially function similarly to natural vessels. 
Two main approaches have been used in designing an optimal scaffold for a 
TEVG: scaffolds composed of biodegradable and resorbable materials, and permanent 
scaffolds made from decellularised blood vessels.
289-291
 As the focus of this work is to 
develop and characterize biomaterials for a multilayered vascular graft, only the former 
of the two categories will be covered in this review. SPUs are highly tunable which 
allows for flexibility in designing biomedical applications as it relates to degradation as 
well as mechanical properties.  Thus with the abundance of polyurethane component 
choices, SPUs have been utilized for various TE scaffolds including several 
cardiovascular scaffolds, Table 1.3. 
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Table 1.3. Polyurethane Tissue Engineering Scaffolds 
Polyurethane Tissue Engineering Scaffolds 
General TE Scaffolds
110,142,160,292-310
 Bone TE Scaffolds
129,292,311-401
 
Muscle TE Scaffolds
129,130,170,402-404
 Cartilage TE Scaffolds
329,331,332,358,375,378,396,405-426
 
Neurological TE Scaffolds
140,351,410,427
 Ligament TE Scaffolds
89,128
 
Skin TE Scaffolds
351,375,410,428-432
 Liver TE Scaffolds
433-438
 
Cardiovascular TE Scaffolds
109,115,129,155,157,160-162,164,165,173,174,176,177,180,296,298,299,344,439-494
 
 
A key functional requirement in the design of TE scaffolds yet to be addressed in 
this review is the rate of degradation needed to ensure proper integration of neotissue 
within the scaffold. It has been shown that components of polyurethane structure can 
have specific effects on degradation.
495
 Several studies have been conducted to help 
understand the effects on degradation specifically caused by the hard segment. Tang et 
al. observed in separate studies the effects of hard segment chemistry and hard segment 
content on the enzymatic degradation of polycarbonate-polyurethanes (PC-PU)s.
225,226
 
The study on hard segment chemistry specifically looked at differences in the 
polycarbonate-polyurethanes synthesized from hexane diisocyanate (HDI), methylene di 
(p-phenyl diisocyanate) (MDI), and hexamethylene diisocyanate (HMDI). Ultimately it 
was concluded that MDI and HMDI degraded at a much slower rate than HDI likely due 
to less hydrogen bonding among the carbonate and urethane linkages in the PC-PU 
synthesized from the latter isocyanate.
225
 Though it was also found that PC-PUs with 
MDI and HMDI were found to initially degrade similarly, at later time points HMDI-
based polyurethanes degraded more.
225
 The same degradation patterns were observed by 
Kim et al. in poly(ester urethane urea)s  synthesized with the same choice of isocyanates 
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for acceleration hydrolysis and enzymatic degradation.
496
 Though Tang and colleagues 
concluded that hydrogen bonding could be a parameter to consider for biostable 
polyurethanes,
225
 the same can also be applied for resorbable polyurethanes intended to 
degrade. 
While the choice of isocyanate can affect the degree of hydrogen bonding and 
ultimately the degradation rate of resorbable polyurethanes, the aforementioned 
isocyanates are not hydrolytically labile. To make the hard segment increasingly labile, 
lysine diisocyanate (LDI) is a common choice due to its known lack of cytotoxic 
degradation byproducts.
310,497-499
 The use of LDI allows urethane linkages to be 
hydrolyzed into lysine products.
310,497
 The effects of the isocyanate following 
degradation have also shown to contribute to further degradation. Bruin et al. have 
hypothesized that when LDI is cleaved, it forms carboxylic acid groups which can 
further catalyze hydrolytic degradation.
500
 Others such as Elliot and colleagues conclude 
that urethanes and ureas can only degrade enzymatically therefore the effects of 
carboxylic acids in the degradation medium are not significant.
214
 
Though the effects of choice and amount of isocyanate in the hard segment of 
polyurethanes have been found to affect the degradation behavior of polyurethanes, the 
chain extender has been shown to contribute as well. For enzymatic degradation, it was 
found by Skarja et al. that the use of an amino acid-peptide based chain extender 
including ester linkages could increase the enzymatic lability of the PUs significantly 
though they were not susceptible to hydrolysis.
209
 Though they did not observe 
degradation behavior, Dahiyat et al. synthesized a series of putrescine based 
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poly(phosphoester urethane)s with chain extenders containing phosphoester linkages 
likely to be hydrolytically labile. In a more recent study by Tatai and colleagues, the rate 
of hard segment hydrolytic degradation was accelerated with the use of a hydrolysable 
chain extender based on poly(DL-lactide) and ethylene glycol. Ultimately, results 
indicated the hard segment’s rate of degradation to be higher than that of the basic 
poly(ε-caprolactone) (PCL) soft segment.501 It can be seen from the aforementioned 
studies that chain extender chemistry is an additional item to consider in designing 
resorbable polyurethanes. 
Despite the observations discussed previously, the composition of the ester-based 
soft segment most often controls the polyurethane’s degradation rate in vitro.502-506 With 
regards to these soft segments, ultimately degradation rate is dependent on the rate of 
medium diffusion through the polymer. One major property associated with medium 
uptake is hydrophilicity known to have a clear effect on the degradation rates of various 
polyesters.
507
 Several studies have synthesized polyurethanes with soft segments 
comprised of hydrophilic and/or hydrophobic components.
208,215,508-511
 A prime example 
of this approach is the use of the poly(ethylene glycol)-poly(propylene oxide)-
poly(ethylene glycol) (PEG-PPO-PEG) triblock, better known as Pluronics
®
. By varying 
the molar ratios of PEG and PPO the hydrophilicity of the polyurethane can be affected. 
In a study by Gorna and Gogolewski, the triblock was included to make the polyurethane 
more hydrophilic was PCL was also included to add hydrophobicity to the polymer as 
well as hydrolytic lability. As expected, evidence of degradation was most prevalent in 
specimens with the highest amount of Pluronics
®
.
208
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Controlling hydrophilicity may be an effective method to tailor degradation rate 
but it is not the only pathway to control water uptake. The crystalline morphology of the 
polyurethane structure can also affect the diffusion rate of degradation mediums. Skarja 
et al. found that polyurethanes with amorphous soft segments increases the rate of 
hydrolysis
511
 while an increase in crystallinity would decrease the degradation 
speed.
215,511
 Despite the differences found in these studies it was concluded that 
hydrophilicity is the more dominant effect in soft segments.
215,511
 
 
1.7 Summary 
Segmented polyurethanes show great promise in developing multilayered 
vascular grafts by providing greater control over graft biomechanical properties which 
ensures long term success in vivo. Using the thermoplastic polymer in a semi-
interpenetrating polymer network further enhances its ability to match the requisite 
mechanical properties needed for successful in vivo deployment of the vascular grafts. 
Silicone networks will help modify the mechanical behavior of the vascular graft to 
better mimic that of native carotid artery tissue.  The use of carbonate-based polyols in 
the soft segment of the SPUs will further enhance the overall biostability of the vascular 
graft and ensure better retention of mechanical properties in the long-term. 
Electrospinning will allow for the further tuning of the vascular graft with optimal fiber 
diameter and orientation giving it the best morphology needed to incorporate a bioactive 
non-thrombogenic intimal layer. Finally, it is believed that the incorporation of a 
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biodegradable component in the vascular graft design coupled with controlled 
electrospun fiber morphology, would allow for restoration of graft vasoactivity. 
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CHAPTER II  
FABRICATION AND INITIAL TESTING OF MULTILAYER VASCULAR 
GRAFTS* 
 
2.1 Introduction 
Traditional synthetic options typically used as small diameter vascular grafts in 
bypass and arterial replacement surgery result in acute and long term re-occlusion rates. 
Early flow obstruction can be attributed to the inherent thrombogenicity of most 
commercially available synthetic materials often causing substantial platelet adhesion 
and aggregation. Long term decreases in patency of distal arterial vasculature can be 
attributed to the synthetic graft’s lack of requisite mechanical properties to match the 
compliance of native tissue without sacrificing burst pressure. Past options have 
provided burst pressures that exceed the properties of autologous veins but the lack of 
compliance has been directly correlated to decreases in rate of 5 year patency.
512
 Thus 
matching compliance with the reinforcing layer has been proven to be just as crucial as 
providing a thromboresistant inner layer. Research has previously addressed these gaps 
by developing new designs that better mimic the properties of native blood vessels,
19,513-
515
 but these attempts have typically resulted in impractical fabrication 
requirements.
18,516-518
 Thus, a novel and inexpensive synthetic design needs to be 
*Excerpts and select figures reprinted with permission from “Multilayer Vascular Grafts 
Based on Collagen-Mimetic Proteins,” by MB Browning, D Dempsey, V. Guiza, S. 
Becerrea, J. Rivera, B. Russell, M. Höök, F. Clubb, M. Miller, T. Fossum, J-F Dong, 
A.L. Bergeron, M. Hahn, and E. Cosgriff-Hernandez, Acta Biomaterialia 2012, 8 (3), 
1010-1021. Copyright (2012) Elsevier. 
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developed that incorporates both the biological and mechanical properties of autologous 
grafts but also allows for the availability provided by current synthetic options. 
Our multilayer graft is expected to successfully provide a thromboresistant inner 
layer that also promotes rapid endothelialization through a Scl2-2 protein based PEG 
hydrogel coating. The bioactive hydrogel has been previously reported to provide 
integrin binding sites known to only allow the binding of endothelial cells;
519
 however 
the hydrogel is not expected to withstand physiological loading.
520-523
 Therefore, our 
reinforcing layer of the multilayer graft must provide the necessary material strength to 
withstand physiological loads, but also retain the requisite mechanical properties needed 
for long term patency. SPUs were selected because of their established biocompatibility, 
durability, and fatigue resistance.
46
 In addition the reinforcing layer of the graft was 
fabricated using electrospinning to provide a porous fibrous architecture expected to 
yield even greater compliance values. Furthermore, the high tunability of SPUs along 
with the modulation of electrospun graft architecture is expected to improve graft 
biomechanical properties beyond reported values from autologous veins. 
The current study focuses on the feasibility of fabricating the composite vascular 
graft. In addition to the well documented complications arising from thrombosis and 
intimal hyperplasia, the graft’s ability to withstand processing effects and surgical 
deployment must also be evaluated. To this end we have electrospun the reinforcing 
layer and characterized its resultant architecture prior to composite fabrication. The 
fibrous sleeve was subject to biomechanical testing to obtain initial trends from graft 
architecture. While it is important to optimize the layers for their separate applications, 
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the overall feasibility of the graft could be the cause of initial device failure prior to 
known complications. Therefore, it is crucial to the overall success of the multilayer 
vascular graft design for the graft to be evaluated for initial performance prior to long 
term studies. 
2.2 Materials and Methods 
 2.2.1 Materials All chemicals were used as received and purchased from Sigma 
Aldrich (St. Louis, MO) unless otherwise noted. 
 2.2.2 SPU Electrospinning BioSpan
®
 (DSM-Polymer Technology Group; 
Berkeley, CA, USA) and Carbothane
®
 (Lubrizol; Wikliffe, Ohio, USA) were dissolved 
at 15 wt% in dimethylacetamide (DMAC) for electrospinning. A 4 mm diameter copper 
rod collector was dipped in a 5 wt% PEG solution in chloroform. After drying, it was 
grounded and positioned 35 cm away from the tip of a blunted 20 gauge syringe needle. 
The SPU solutions were dispensed at a rate of 1.0 mL per hour with a syringe pump 
(KDS 100, KDS Scientific) as a voltage of approximately 14 kV was applied to the 
needle tip using a high voltage source (Gamma High Voltage, Ormond Beach, FL, USA) 
for 2 to 8 hours.
524
 After the designated time period, the copper rod with the mesh was 
placed in water overnight to dissolve the inner PEG layer, and the mesh was removed 
from the rod while submerged. High resolution images of electrospun fiber mats were 
captured using a field emission – scanning electron microscope (JSM-7500F, JEOL) 
operated at 2 kV to confirm fibrous morphology. Fiber diameter was quantified using a 
pixel-to-length ratio approximation on 25 randomly selected fibers in the micrographs. 
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 2.2.3 Multilayer Graft Fabrication Mesh sleeves were taken through a graded 
ethanol/water soak (70%, 50%, 30%, and 0%; 30 minutes each) to ensure hydration and 
penetration of the aqueous hydrogel precursor solutions into the mesh prior to 
polymerization. The pre-wetted meshes were placed in a cylindrical mold with an inner 
glass mandrel (3 mm OD). Hydrogel solutions were pipetted between the mandrel and 
the hydrated mesh (4 mm ID) and crosslinked as described in Section 2.3, Figure 2.1. 
Given that the inner diameters of the mesh and the multilayer graft (i.e. the hydrogel 
layer) were held constant, the outer diameter of the multilayer graft was dependent on 
the thickness of the electrospun mesh. In these studies, the electrospun mesh thickness 
was modulated from approximately 0.2 to 1.2 mm, resulting in graft wall thickness 
between 0.7 and 1.7 mm and corollary graft outer diameters between 4.4 and 6.4 mm. 
 
Figure 2.1. Multilayer graft fabrication. (A) Fabrication process of multilayer grafts. 
(B) Multilayer graft. 
 
 29 
 
 2.2.4 Multilayer Graft Biomechanical Properties To determine the dependence 
of multilayer graft suture retention strength, burst pressure and compliance on the 
thickness of the electrospun mesh layer, BioSpan
®
 was electrospun for 2 to 8 hours to 
form reinforcing meshes with varied thicknesses. Electrospun meshes were then 
combined with 20 wt% poly(ethylene glycol)-diacrylate (PEGDA) (6 kDa) hydrogels for 
testing. Graft suture retention strength was determined in accordance with the straight 
across procedure described in the American National Standard Institute – Association for 
the Advancement of Medical Instruments VP20-1994. Briefly, 18 mm long tubular 
samples were cut lengthwise to obtain rectangular strips (approximately 12 mm wide). A 
5.0 commercial PDS II monofilament suture (Ethicon, Inc) was inserted 2 mm from the 
short edge of the sample, looped, and tied. The lower end of the sample and the suture 
loop were secured in the grips of a uniaxial load test machine (Instron 3342) and 
extended at a rate of 100 mm/min until the suture pulled through the sample wall. Suture 
retention strength was considered to be the maximum force recorded prior to sample 
failure. 
 For burst pressure and compliance assessment, a nonporous latex tube lining was 
inserted into multilayer grafts (35 mm long). Burst pressure was determined from a 
method adapted from Sarkar et al.
525
 Deionized water was pumped into the latex tubes at 
a rate of 140 mL/min using a syringe pump (KD Scientific), and the pressure was 
measured using a high pressure gauge (0 to 60 psi pressure range, NoShok) connected 
downstream of the graft. The ends of the grafts were firmly secured and sealed to 
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prevent leaking. The maximum pressure prior to construct failure was recorded as the 
burst pressure. 
 The static compliance of separate latex-lined grafts was measured as previously 
described.
526
 Briefly, a syringe pump (Harvard Apparatus) was used to subject the 
multilayer grafts to a pressure ramp (0-150 mmHg). Intraluminal pressure was 
monitored using standard in-line strain gauge pressure transducers (Merit Medical, South 
Jordan, UT), and the outer diameter was measured with a He-Ne laser micrometer 
(BenchMIke, Lasermike). Compliance (C) was calculated from the recorded pressure, P, 
and diameter, D, according to the following equation: 
C 
 D
D   P
 
D    D  
D     
 
 2.2.5 In Vivo Acute Thromboresistance All procedures were approved by the 
Institutional Animal Care and Use Committee. Multilayer grafts (3 cm in length, 4 mm 
inner diameter) were implanted in a 6 month old Yucatan miniature pig (30-40 kg) using 
a previously described technique.
527
 Briefly, anesthesia was induced by intramuscular 
injection of Telazol (5 mg/kg) and buprenorphine (0.01-0.05 mg/kg) followed by 
intubation and administration of isoflurane (2-4% MAC) in 100% oxygen for 
maintenance of a surgical plane of general anesthesia. Using sterile technique, an 8-12 
cm incision was made in the ventral midline of the neck. The carotid arteries were 
sequentially exposed and vascular clamps placed at each end of the area of interest on 
the artery to provide temporary vessel occlusion. An end-to-end anastomosis was 
performed using a continuous pattern of 7-0 prolene sutures. A multilayer graft with 
PEG-Scl2-2 (10% 3.4 kDa, 12 mg protein mL
-1
) was implanted on the left side, and a 
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PEGDA (10% 3.4 kDa) control graft was implanted on the right side. After confirming 
patency and hemostasis, subcutaneous tissues and skin were closed routinely. Digital 
subtraction and 3-D angiography were performed via the transfemoral technique with 
systemic anticoagulation using heparin after placement of the sheath and maintenance of 
activated clotting lines of 2-3x baseline in order to prevent thromboembolic 
complications related to the procedure itself. After removal of the catheter and sheath, 
the animal was maintained under anesthesia for 5 hours. The patency and anatomy of the 
grafts were assessed using vascular Doppler and two dimensional ultrasound imaging 
techniques. The study subject was then heparinized and humanely euthanized while still 
under general anesthesia. The carotid arteries were carefully removed for further 
evaluations. 
 
2.3 Results and Discussion 
 2.3.1 Electrospun architecture Prior to biomechanical property evaluation of the 
electrospun reinforcing layer, the fiber morphology was first characterized to ensure 
consistent reliable fiber deposition. The macroscopic view of a harvested electrospun 
SPU mesh tube, Figure 2.2a, illustrates an apparent consistent graft size and mechanical 
integrity throughout full length which suggests fibers are deposited evenly throughout 
the process. Resultant fiber morphology observed on the microscopic scale, Figure 2.2b, 
exhibited minimal variation in fiber diameter (1.6 ± 0.1 µm) as well as minimal fiber 
fusions expected to favorably affect graft compliance. In addition, consistent increases in 
graft thicknesses ranging from 0.21 ± 0.06 mm up to 1.19 ± 0.17 mm were measured 
 32 
 
from the scanning electron micrographs. These changes in wall thickness, assuming no 
effect on fiber morphology with increased deposition time, are expected to influence 
graft biomechanical properties. 
 
Figure 2.2. Reinforcing electrospun mesh tube. (A) Electrospun SPU mesh tube. (B) 
Representative SEM image of fibrous SPU mesh tube. Cross-sectional views of (C) low 
thickness tube (wall thickness ≈  . 7 mm), (D) medium thickness tube (wall thickness ≈ 
 .36 mm), and (E) high thickness tube (wall thickness ≈  .7  mm). 
 
2.3.2 Multilayer Graft Biomechanical Properties The long term in vivo success 
of our multilayer graft design is highly dependent on the resultant biomechanical 
properties of the electrospun reinforcing layer. The grafts are expected to provide the 
requisite suture retention strength needed for implantation as well as burst pressure and 
compliance values comparable to reported autologous vein properties. While burst 
pressure and suture retention strengths have already been replicated in current synthetic 
options,
512
 compliance values are substantially lower than autologous veins which 
resulted in poor patency after 5 years. Stewart et al. hypothesized that low compliance  
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grafts do not distend as wide as distal arteries creating a disruption in flow patterns 
downstream of the graft.
16
 Consequently, stagnation points are created along the walls of 
the native vasculature which the arterial wall attempts to eliminate via intimal 
hyperplasia to reach original mean shear stress values.  Graft wall thickness was changed 
by modulating electrospinning time in an attempt to control graft biomechanics, Table 
2.1 
Effects on graft biomechanical properties with increasing mesh thickness were 
monitored. A distinct positive correlation was found between graft thickness and burst 
pressure as well as suture retention strength. Burst pressure was found to increase from 
534 ± 84 mmHg up to 1404 ± 40 mmHg which translated to 163% increase over the full 
range of graft thicknesses. The effect of thickness on burst pressure was attributed to a 
materials known dependence on construct dimensions, where the increase in graft 
thickness can be related to an increase in cross-sectional area. As a result the material, 
whose finite stress limit is not expected to change, can withstand more force with a 
given increase in cross-sectional area.
528
  
 
Table 2.1. Biomechanical properties of multilayer vascular grafts. 
Thickness 
(mm) 
Burst Pressure 
(mmHg) 
Suture Retention 
Strength (gf) 
Compliance 
(%/mmHg x 10
-4
) 
0.21 ± 0.06 534 ± 84 406 ± 124 5.9 ± 1.4 
0.39 ± 0.06 665 ±   3 (↑  5%) 76  ±  3  (↑   %) 3.6 ±  .  (↓ 39%) 
0.72 ± 0.06 9 5 ±   6 (↑ 69%)  39  ± 3 6 (↑    %)  .7 ±  .  (↓ 5 %) 
1.19 ± 0.17      ±    (↑  63%)  73  ± 33 (↑ 3 7%) 1.8 ±  .  (↓ 69%) 
Saphenous 
Vein
512
 
1680 ± 307 196 ± 2 4.4 ± 0.8 
 (average ± standard deviation; n=16 for compliance, n=4 for burst pressure) 
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As for graft compliance, only the thinnest graft provided a compliance higher 
than reported autologous values which unfortunately could only withstand a burst 
pressure of less than a third of the vein’s property. The inverse effect of thickness on 
compliance can be related to the definition of elastic modulus where, the increased stress 
response of a graft due to increased wall thickness, is then expected to increase the 
modulus as well and thus decrease compliance. This negative correlation has been 
demonstrated previously in the literature with current synthetic grafts.
512
 
With regards to suture retention strength, the lowest thickness reached strengths 
of 406 ± 124 gf which already match autologous properties. Increased thickness up to 
highest value was found to further increase the suture retention strength more than 
threefold. This suggests that all multilayer vascular grafts can provide the suture 
retention sufficient for implantation.  
While compliance values exceeded autologous graft properties in the samples 
with the lowest thickness, the burst pressure loss limited grafts to only achieving one 
property at a time while autologous graft anisotropy allows for simultaneous properties. 
This limitation indicates that the tunability of the current SPUs along with architectural 
tailoring using electrospinning are both insufficient to achieve simultaneous 
improvements in burst pressure and compliance. A novel approach involving changes to 
electrospun SPU chemistry and processing effects was then explored and will be 
discussed in the next chapter. 
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2.3.3 In Vivo Acute Thromboresistance Multilayered grafts were implanted into 
a miniature Yucatan pig for 5 hours. During the implantation surgery, grafts were found 
to hold sutures and retain physiological blood flow, Figure 2.3a, suggesting that graft 
biomechanical properties were sufficient for use in vivo. Furthermore, the examination 
through intravital imaging exhibited excellent patency on the inner layer with no effects 
on blood flow or arterial narrowing observed. In addition, evidence of thromboresistance 
was characterized via angiography, gross pathology, and micro tomography, Figure 
2.3b-d, which was then corroborated with acute in vitro testing.
528
 Overall the multilayer 
graft was found to perform very favorably in vivo for an acute time frame (5 hours). 
While effects of compliance could not be examined in vivo, longer implantation testing 
is planned which would allow for that evaluation. 
 
 
Figure 2.3. Multilayer vascular graft implantation. (A) Implantation into porcine carotid 
artery. In vivo acute thromboresistance was established via (B) angiography, (C) gross 
pathology, and (D) micro tomography.  
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2.4 Conclusions 
 In this chapter, the feasibility of our multilayered vascular graft design was 
evaluated for potential use in small-diameter applications. Consistent fibrous 
morphology of the electrospun graft was demonstrated with minimal fusions. The 
resultant meshes were then coated with the PEG hydrogel layer and testing for 
compliance and burst pressure, which revealed a strong correlation between mesh 
thickness and compliance/burst pressure. Despite achieving favorable compliance levels 
with the thinnest electrospun grafts, the inverse relationship between burst pressure and 
compliance brought the grafts burst strength down well below reported autologous vein 
properties. In addition to promising initial biomechanics data, the multilayer graft’s 
suturability and burst pressure were found to be sufficient in vivo along with evidence of 
acute thromboresistance after 5 hours of implantation. It should be noted, that only the 
graft design feasibility was tested in this chapter. The favorable in vitro biomechanical 
testing and acute in vivo implantation results have provided the justification for further 
optimization of the reinforcing layer’s biomechanical properties through more complex 
approaches presented in the next chapter. 
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CHAPTER III  
SYNTHESIS OF A PCU/PDMS SEMI-INTERPENETRATING NETWORK THAT 
MATCHES THE MECHANICAL BEHAVIOR OF NATIVE ARTERIES 
 
3.1 Introduction 
A compliance mismatch between the graft and artery has been previously 
reported to cause flow separation and stagnation zones in vasculature downstream from 
synthetic grafts.
16
 This decrease in mean shear stress experienced along the vascular wall 
induces a physiological response to increase the arterial wall thickness via intimal 
hyperplasia in an attempt to restore the target wall shear stress.
14
 Given the known 
correlation between graft compliance and patency of autologous and synthetic small 
diameter vascular grafts,
512
 this biomechanical property has become one of the key 
design requirements in the development of improved arterial prostheses. Along with the 
initial testing results of our preliminary multilayer graft design, no known homopolymer 
has been shown to provide the appropriate compliance without sacrificing suture 
retention strength and/or burst pressure.  
We have selected SPUs for our multilayer design due to their high tunability 
which provides multiple mechanisms to tailor graft mechanical properties to enhance 
clinical performance. Early polyurethane grafts such as the Corvita, Thoratec, and 
PulseTec vascular grafts were developed as an alternative to the standard Dacron and 
GoreTex grafts with modest improvements in compliance.  However, compliance values 
were still well below autologous standards.
84
 Newer commercial SPU grafts such as the 
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UCL-Nano™ and Myolink grafts, now available in Europe, have exhibited improved 
compliance values well over traditional homopolymer options.
529,530
 Unfortunately, no 
record of the burst pressure of these grafts is available indicating that it meets minimum 
standards for implantation. SPU materials have been previously explored in our 
laboratory as an option for an electrospun reinforcing layer of a multilayered vascular 
graft.
528
 Despite outperforming current polyurethane grafts in achieving high compliance 
values by modulating graft architecture with electrospinning parameters, the graft did 
not retain burst pressure comparable to current grafts.
529
 Furthermore, an inverse 
correlation between burst pressure and compliance was still observed making it difficult 
to match the high burst pressure and high compliance of native arteries.  
Although polyurethanes are similar to arteries in their high elastic recovery at 
low strains and high tensile strength, arteries typically display an earlier and more robust 
strain hardening region.
49
 Arterial tissue is composed of alternating layers of elastin and 
collagen with elastin serving as the key contributor at low strains and collagen becoming 
more dominant at high strains.
531
 The similarity in the SPU stress response may be 
attributed to the microphase-separated morphology with elastomeric stretching of the 
soft segment matrix dominant at low strains followed by hard domain rotation/shear and 
strain-induced crystallization of the soft segment as strain is increased.
532
 To reduce 
modulus in a polyurethane to improve compliance, a lower hard segment content is 
typically chosen; however, this also results in reduced tensile strength which has been 
correlated with lower burst pressures.
533
 Therefore, a new strategy must be employed 
beyond typical segmental chemistry modifications to better match arterial properties 
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without sacrificing the desirable high elastic recovery and tensile strength of the 
polyurethane. 
Interpenetrating polymer networks (IPNs) have been explored in biomedical 
devices due to their ability to maintain the desirable properties of multiple materials.
534-
538
 Similarly, semi-interpenetrating polymer networks (semi-IPNs) replace one of the 
covalently crosslinked networks with a linear component which allows for separation 
without change in chemical composition and ease of processing. For this work, semi-
IPNs based on a linear SPU was selected to allow for full use of their attractive 
characteristics without sacrificing key mechanical properties. A crosslinked silicone 
network was selected as the second component of the semi-IPN given the prevalence of 
the material class in biomedical devices
539-541
 and demonstrated biostability.
542
 Previous 
research has explored employing an SPU coupled with a poly(dimethylsiloxane) 
(PDMS)-based macromer to improve the compliance of a vascular graft.
81
 The authors 
attributed the increase in compliance to the proposed plasticization of the physically 
crosslinked SPU network by the siloxane molecules.  
In the present study, we propose to implement this PDMS-SPU semi-IPN design 
in an electrospun graft to improve compliance while maintaining burst pressure. The 
effect of semi-IPN chemistry on compliance and burst pressure of electrospun grafts 
with similar thickness and fiber morphology was determined. Dynamic mechanical 
analysis (DMA), differential scanning calorimetry (DSC), and attenuated total 
reflectance (ATR)-FTIR were used to assess microphase morphology and correlate with 
observed biomechanical properties to identify key structure-property relationships. 
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Finally, the biomechanical properties of these electrospun SIPN grafts were then 
compared to reported values of current autologous grafts to assess their potential as 
arterial prostheses. 
 
3.2 Materials and Methods 
 
3.2.1 Materials Poly(carbonate urethane) (PCU) Carbothane
®
 PC3575A was 
purchased from Lubrizol (Boston, MA) and used as received. Methacryloxypropyl 
terminated PDMS and (3-Acryloxy-2-hydroxypropoxypropyl) terminated PDMS, 
Figure 3.1, were purchased from Gelest, Inc. (Morrisville, PA) and used as received. 
The PDMS-dimethacrylate (PDMS-DMA) macromer had a reported weight average 
molecular weight (MW) range of 380-550 Da and the PDMS-diacrylate (PDMS-DA) 
macromer had a reported MW range of 600-900 Da. Poly(ethylene glycol) (PEG) with 
MW of 35 kDa, N,N’-dimethylacetamide (DMAC), chloroform, and benzoyl peroxide 
(BPO) were purchased from Sigma Aldrich (Milwaukee, WI) and used as received. 
 
 
Figure 3.1. Chemical structures of PDMS macromers 
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3.2.2 Electrospun Graft Fabrication 
3.2.2.1 Solution Preparation PCU pellets were subject to a minimum of 24 hours 
vacuum drying at ambient temperature prior to use. DMAC and chloroform were stored 
over molecular sieves prior to solution preparation to avoid minimize water content. 
PCU solutions were prepared by dissolving the SPU pellets at 18 wt% in DMAC and 
purged with nitrogen.  SIPN solutions were made by first mixing DMAC and chloroform 
at a 3:1 ratio followed by the addition of 1 wt% thermal initiator, BPO. The PDMS-
DMA macromer was then added at 5, 10, or 20 wt% concentrations of the original 18 
wt% solute and allowed to dissolve before adding the remaining PCU component, 
????? 3.1.  Solution ?viscosities were adjusted as ?needed ? to? maintain a viscosity of 10 
Pa·s to avoid variation in electrospun architecture. 
543
 A 25 wt% solution of PEG 35 kDa 
in chloroform was also prepared for use as a sacrificial inner layer to aid in graft 
harvesting. 
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Table 3.1. Electrospun semi-IPN compositions 
 
Percentage 
Carbothane
®
 
3575A 
Percentage 
PDMS 
Macromer 
Solvent 
BPO 
Initiator 
Content 
Pure 
PCU 
100% 0% DMAC 
0% 
5/95 
DMA 380 
95% 5% DMA 380 3:1 DMAC:CHCl3 
1% 
10/90 
DMA 380 
90% 10% DMA 380 3:1 DMAC:CHCl3 
1% 
20/80 
DMA 380 
80% 20% DMA 380 3:1 DMAC:CHCl3 
1% 
10/90 
DA 600 
90% 10% DA 600 3:1 DMAC:CHCl3 
1% 
(DMAC   N,N’-dimethylacetamide, CHCl3 = Chloroform, BPO = Benzoyl Peroxide) 
 
 
3.2.2.2 Electrospinning Process All electrospinning runs were performed inside 
an enclosed acrylic box to maintain consistent levels of approximately 50% relative 
humidity and 21°C temperature.  Prior to electrospinning PCU or SIPN solutions, a 
sacrificial layer of PEG was electrospun onto 5 mm mandrels to maintain fibrous 
morphology on layer while also providing separation between the PCU and mandrel. 
Briefly, the 25 wt% PEG 35 kDa solution was poured into a 10 mL glass syringe 
equipped with a blunted 20 gauge needle. The solution was dispensed out of the needle 
at 0.5 mL/hr using a KDS 100 syringe pump (KD Scientific, Holliston MA) with a 
distance to collector (DTC) of 52 cm onto the stainless steel mandrel rotating at 500 
rpm. A positively charged voltage of 14 kV was applied to the tip of the 20 gauge needle 
and a negatively charged 2 kV was applied to the mandrel using high voltage sources 
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purchased and used as received from Gamma High Voltage (Ormond Beach, FL). The 
PEG 35 kDa solution was allowed to spin for 5 minutes before the syringe was replaced 
with one loaded with Carbothane
®
 or a semi-IPN solution. The PCU and SIPN solutions 
were subject to the same parameters except the positive voltage was increased to 
approximately 20 kV and the negative to 5 kV.  All PCU/SIPN solutions were 
electrospun for 2 hours and 15 minutes to achieve a graft thickness of approximately 0.2 
mm. Solutions were electrospun for 4-6 hours for mesh thicknesses of 0.4 mm. 
3.2.2.3 Heat Treatment Electrospun meshes were soaked overnight in deionized 
water to dissolve the inner electrospun PEG layer and facilitate the removal of the 
electrospun grafts from the mandrel.  The grafts were then dried under vacuum overnight 
to remove excess water.  Finally, the electrospun SIPN grafts were subject to a 12 or 24 
hour heat treatment on 5 mm diameter PTFE rods to covalently crosslink the siloxane 
network.  A set of Carbothane
®
 electrospun grafts were also heat treated to isolate the 
effects of the curing conditions on the electrospun PCU material properties. 
3.2.3 Graft Characterization Grafts were cut into 4 cm long pieces for all 
materials testing. Characterization was performed on both as-spun and heat-treated grafts 
to observed effects of the curing cycle on electrospun fiber architecture and properties. 
Fiber morphology of electrospun grafts were observed using scanning electron 
microscopy (SEM). Changes in viscoelastic response were monitored using dynamic 
mechanical analysis (DMA). Microphase morphology was then further investigated with 
differential scanning calorimetry (DSC) and ATR-FTIR spectroscopy. Crosslinking of 
covalent PDMS networks was confirmed with NMR spectroscopy. 
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3.2.3.1 Scanning Electron Microscopy (SEM) Fiber morphology was examined 
using SEM with a JEOL NeoScope JCM-5000 (Tokyo, Japan) at a 5 kV acceleration 
voltage. Specimens were coated with approximately 4 nm of gold using a Cressington 
Sputter Coater 108 (Watford, England) prior to imaging. Similar fiber diameter and 
junction quality of as-spun grafts were confirmed prior to heat treatment and microphase 
morphology/biomechanical analysis. 
3.2.3.2 Microphase Morphology Analysis Effects of electrospinning and heat 
treatment on the material properties of the Carbothane
® 
and semi-IPN grafts were 
examined using DMA, DSC, and ATR-FTIR analysis.  DMA was conducted with a TA 
RSA3 on grafts cut into strips of approximately 5 cm in width.  Specimens were subject 
to a temperature ramp from -90°C to 100°C at a rate of 5°C/min while under a 0.1% 
cyclic strain at 1 Hz frequency.  DSC thermograms (n=3) were collected on specimens 
of approximately 10-15 mg which were subjected to a temperature ramp of -90°C to 
100°C with the same rate under nitrogen gas using a TA DSC Q100 (Houston, TX).  For 
DSC, all analysis was performed on the first scan to examine processing effects from 
electrospinning and/or heat treatment. Finally, proposed effects on microphase 
morphology were corroborated by using ATR-FTIR to examine changes in hydrogen 
bonding within the hard domains of the electrospun PCU. Briefly, 32 spectral scans of as 
spun and heat treated electrospun grafts were taken and averaged over the wavenumber 
range of 4000 to 700 cm
-1
 using a Bruker ALPHA equipped with a Germanium ATR 
single reflectance module. The carbonyl wavenumber region (1800 to 1600 cm
-1
) of 
segmented polyurethanes was monitored to examine changes in the hydrogen bonding of 
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the urethane carbonyl as an indicator of microphase morphology.
544
 Specifically, the free 
urethane carbonyl absorbance near 1730 cm
-1
 was expected to be reduced while the 
hydrogen bound carbonyl absorbance at 1700 cm
-1
 would increase with evidence of 
microphase separation. 
3.2.3.3 Biomechanical Testing Static compliance of each graft was measured 
using a method described previously.
526
 Briefly, a nonporous latex tube was inserted 
inside each graft prior to testing. The grafts were subject to a pressure ramp from 0 to 
150 mmHg using deionized water dispensed via a syringe pump connected to the latex 
tube. A standard in line strain gauge pressure transducer from Merit Medical (South 
Jordan, UT) was used to measure intraluminal pressure while the outer diameter of the 
graft was measured with a Lasermike He-Ne laser micrometer. Compliance (C) was 
calculated using the following equation: 
  
  
     
 
        
      
,   (1) 
where ΔP is change in pressure and D120 and D80 are the graft outer diameters at 120 and 
80 mmHg intraluminal pressure, respectively. Compliance values were recorded 5 times 
on each graft and values from each graft were averaged to obtain the reported value 
(n=15 total). Burst pressure testing was then performed on the same graft by pumping 
deionized water into the graft at 100 mL/min until the electrospun mesh failed (n=3).
525
 
The maximum pressure upon failure was measured and recorded using a NoShok high 
pressure gauge ranging from 0 to 60 psi (Berea, OH), which was then converted to 
mmHg. Both burst pressure and compliance were performed under standard laboratory 
conditions (25°C) and simulated physiological conditions (37°C, high relative humidity). 
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Prior to testing at simulated physiological conditions, grafts were equilibrated in water at 
37ºC overnight. 
3.2.3.4 Confirmation of Silicon Network Formation Nuclear magnetic 
resonance (NMR) spectroscopy was utilized to determine the extent of silicone network 
formation in the semi-IPNs after heat treatment. Briefly, as-spun and heat-treated grafts 
were dissolved in deuterated chloroform (CdCl3) at a concentration of 10 mg/mL. 
Solutions were allowed to settle in order to identify gel fractions, if any, formed by the 
crosslinked network. Small 1 mL samples were then extracted from the solute fraction 
and analyzed with H NMR (300 MHz, CDCl3): PDMS DMA 3   δ  .   (s, 3H, -CH3), 
0.52-0.57 (m, 2H, -CH2-), 1.62-1.73 (m, 2H, -CH2-), 1.95 (s, 3H, -CH3), 4.07-4.12 (m, 
2H, -CH2-), 5.5  (s,  H,  CH ), 6.   (s,  H,  CH ), PDMS DA 6   δ  . 3-0.12 (m, 
3H, -CH3), 0.47-0.58 (m, 2H, -CH2-), 1.52-1.68 (m, 2H, -CH2-), 3.39-3.55 (m, 2H, -
CH2-), 3.85-3.90 (m, 1H, -CH-), 4.18-4.29 (m, 2H, -CH2-), 5.80-5.97 (m, 1H, =CH2), 
6.07-6.22 (m, 1H, -CH), 6.38-6.53 (m, 1H, =CH2). Following initial characterization, 
changes in spectral peaks of the semi-IPNs characteristic only of the silicone component 
were monitored for potential crosslinking of the PDMS macromer. 
3.2.4 Statistical Analysis A student’s T-test was performed to determine 
statistical significance between groups of data. All comparisons were made with a 95% 
confidence interval. (α  . 5) 
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3.3 Results and Discussion 
3.3.1 Initial Graft Characterization Synthetic vascular grafts were fabricated 
by electrospinning 18 wt% solutions of  Carbothane
®
 dissolved in DMAc or varied 
blends of Carbothane
®
 and up to 20% silicone macromer DMA 380 or DA 600 dissolved 
in 3:1 DMAc:CHCl3. All solutions were electrospun for approximately 2-3 hours to 
produce grafts of approximately 0.2 mm thickness. Similar fiber morphologies of each 
electrospun fiber mesh were then confirmed with SEM to isolate material composition 
changes from architectural effects. Following morphology comparison, all 0.2 mm thick 
electrospun PCU/PDMS blends were subjected to a 12 hour 50°C heat treatment to 
facilitate silicone network formation for the overall semi-IPN. Electrospun PCU grafts 
were also subject to the same heating cycle to observe the effects of heat treatment on 
PCU grafts. 
All as-spun fiber meshes had similar fiber morphologies in both PCU and all 
PCU/PDMS compositions, Figure 3.2 which indicates the morphology was unaffected 
by PDMS macromer content. Heat treatment of all grafts produced fiber junctions with 
higher percent fusion within the mesh than their as-spun counterparts. The increase in 
fusion at fiber junctions was attributed to the softening of the fibers during the 12 hours 
at 50°C. These decreases in fiber interbond arc length545 has been cited as a direct source 
of increases in modulus and ultimate elongation in the circumferential direction of a 
tubular graft.
545-547
 Furthermore, this softening was enhanced with higher concentrations 
of the PDMS DMA 380 macromer and to a greater extent in the 10/90 DA 600 system. 
Given our recent report on the effect of increased fusion on graft biomechanical 
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properties, compliance was expected to decrease and burst pressure was expected to 
increase with this change in fiber architecture.
533
 
 
 
Figure 3.2. Scanning electron micrographs of 0.2 mm thick electrospun grafts 
comparing fiber morphology before and after heat treatment (50°C, 12 hours) 
 
3.3.2 Graft Biomechanical Properties Compliance and burst pressure 
measurements were conducted on 0.2 mm thick electrospun Carbothane
®
 grafts and 
semi-IPN grafts with varied levels of PDMS DMA 380 or PDMS DA 600 macromer. 
Prior to heat treatment to crosslink the silicone macromers, compliance of as-spun grafts 
increased and burst pressure decreased with the presence of the silicone macromer, 
Table 3.2. This was attributed to the low glass transition temperature (Tg) of the silicone 
macromer
548
 and the disruption of soft segment crystallinity and hydrogen bonding in 
the polyurethane.
81
 An exception to this trend was observed in the 10/90 PDMS DA 600 
grafts which exhibited an increase in compliance and an increase in burst pressure over 
as-spun Carbothane
®
 grafts. This unexpected phenomenon was attributed to premature 
initiation of PDMS DA 600 crosslinking during the electrospinning process. A low level 
of crosslinking prior to heat treatment was confirmed by the loss of the acrylate peaks in
 49 
 
the NMR spectra of the as-spun graft as compared to the polymer solution. This effect 
was likely not observed by the methacrylate components due to the lower reactivity of 
methacrylate groups compared to acrylates,
549,550
 which limited the possibility of radical 
initiation in the PDMS DMA grafts. A 12 hour heating cycle at 50°C was then applied to 
grafts to covalently crosslink the unreacted silicone macromers. Carbothane
®
 grafts were 
subjected to the same treatment to monitor changes to the polyurethane component of 
the semi-IPN meshes. 
 
Table 3.2. Initial biomechanical properties of as spun and heat treated electrospun grafts 
 Carbothane 
5/95 
DMA 380 
10/90 
DMA 380 
20/80 
DMA 380 
10/90 
DA 600 
As 
Spun 
Compliance 3.8 ± 1.0 6.7 ± 1.2 4.2 ± 0.5 5.0 ± 1.2 4.7 ± 0.4 
Burst 
Pressure 
1188 ± 101 1103 ± 39 991 ± 220 901 ± 130 2069 ± 22 
Heat 
Treated 
Compliance 4.7 ± 0.8 5.9 ± 0.7 7.4 ± 0.8 3.7 ± 0.5 6.5 ± 1.9 
Burst 
Pressure 
1470 ± 73 1246 ± 151 905 ± 101 1036 ± 136 2322 ± 150 
(average ± standard deviation; n=15 for compliance, n=3 for burst pressure; graft 
thickness = 0.2 mm, 50°C, 12 hours) 
 
3.3.2.1 Effect of Heat Treatment on Carbothane
®
 Grafts Interestingly, both 
compliance and burst pressure of Carbothane
®
 grafts increased following heat treatment. 
Compliance increased from 3.8 ± 1.0 to 4.7 ± 0.8 %/mmHg x 10
-4
 and 
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burst pressure increased from 1190 ± 100 to 1470 ± 70 mm Hg. Changes in chemical 
structure, fiber architecture, and polyurethane microphase morphology after heat 
treatment of the Carbothane
®
 grafts were investigated to determine the cause of the 
observed improvements in biomechanical properties. No changes in structure were 
observed in proton NMR spectra and SEM analysis of the fiber morphology displayed 
minimal effects of heat treatment, Figure 3.2. Microphase morphology before and after 
heat treatment was then examined using DMA. The storage modulus plot of the as-spun 
Carbothane
®
 exhibited a broad Tg of the polycarbonate soft segment at approximately -
9°C and an additional melting transition temperature (Tm) at 39°C, Figure 3.3a. In 
comparison to the storage modulus plot of a cast Carbothane
®
 film, the electrospun graft 
displayed a much broader Tg with a strong melting peak at a lower melting temperature 
(39ºC vs 63ºC). Eceiza et al. reported a similar transition at 45ºC in the storage modulus 
plot of a poly(carbonate urethane) and assigned it to melting of crystalline soft 
domains.
551
 Therefore, it was hypothesized that alignment of soft segment chains during 
electrospinning enhanced crystallization and limited phase separation, as evidenced by 
the increased breadth of the Tg. Similar behavior was observed in electrospun 
polycaprolactone-based polyurethanes as compared to the cast film.
552
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Figure 3.3. DMA storage modulus plots of 0.2 mm thick electrospun grafts comparing 
effects of (A) heat treatment (12 hours at 50°C) on Carbothane, (B) PDMS macromer 
content on heat treated specimens, and (C) PDMS macromer Mw on heat treated 
specimens 
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Following heat treatment, a reduction in soft segment crystallization (H = 18 ± 
2 vs H = 12 ± 3) in the Carbothane® DSC thermogram Figure 3.4 was accompanied by 
reduced breadth of the soft segment Tg in the storage modulus plot indicative of 
improved phase separation, Figure 3.3a.
553,554
 Infrared spectroscopy has previously been 
used to assess phase separation from an analysis of the extent of hard segment hydrogen 
bonding.
555
 However, this assessment was inconclusive in the PCU given the 
convolution of the urethane carbonyl region with the carbonyls of the polycarbonate-
based soft segment. Nevertheless, the DSC and DMA analyses provides strong evidence 
that the improvement in biomechanical properties of the Carbothane
®
 grafts was due to 
reduced soft segment crystallinity and enhanced microphase separation after heat 
treatment. Specifically, reduced crystallinity was expected to enhance the flexibility of 
the soft segment matrix and reduce modulus which has been linked to compliance.
533
 
The enhanced burst pressure was attributed to the increase in phase separation and order 
of the hard domains. Similar annealing effects have resulted in increased polyurethane 
tensile strength
556
 which has been correlated with increased burst pressure.
533
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Figure 3.4. DSC thermograms of 0.2 mm thick electrospun Carbothane
®
 and heat 
treated PCU/PDMS macromer blends (12 hours, 50°C) 
 
 
3.3.2.2 Effect of Heat Treatment on Semi-IPN Grafts The effect of heat 
treatment on the compliance and burst pressure of semi-IPN grafts varied based on the 
macromer chemistry and macromer concentration. Biomechanical properties of 5/95 
PDMS DMA 380 grafts were unchanged after heat treatment. The enhanced phase 
separation observed in the Carbothane
®
 control grafts upon heat treatment was not 
observed, Figure 3.3b.  In contrast, heat treatment of the 10/90 PDMS DMA 380 graft 
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resulted in a substantial increase in compliance beyond previously reported saphenous 
vein values
512
 but no effect on burst pressure. Finally, the 20/80 PDMS DMA 380 graft 
exhibited a small increase in burst pressure and a substantial decrease in compliance. The 
observed differences in biomechanical properties as a function of macromer content and 
chemistry were hypothesized to be a result of differences in fiber architecture, silicone 
network formation and polyurethane phase morphology. Fiber architecture changes were 
assessed with SEM, as described above, with particular attention given to the extent of 
fiber fusion. Silicone network formation was assessed using proton NMR of the silicone 
sol fraction present in semi-IPNs after heat treatment. Finally, the effect of silicone 
macromer on phase morphology and soft segment crystallinity was assessed using DMA 
and DSC, respectively.  
An increase in fiber fusion was observed with increasing DMA 380 
concentration, Figure 3.2. We have previously demonstrated that increasing fusion can 
result in enhanced burst pressure and decreased compliance. Although not statistically 
significant, there is an overall trend of increasing burst pressure with increasing 
concentration of the DMA 380, Table 3.2. There was little improvement observed in 
burst pressure with heat treatment for any of the DMA 380 semi-IPN grafts. The degree 
of crosslinking assessed by the silicone present in the NMR spectra of the sol fraction 
was low for both the 5/95 and 10/90 semi-IPNs. It was hypothesized that this low level 
of crosslinking was insufficient for mechanical reinforcement. The 20/80 PDMS DMA 
380 graft did exhibit more crosslinking; however, the network formation remained 
insufficient to cause a significant increase in burst pressure. In contrast, minimal silicone 
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in the sol fraction of the heat treated 10/90 600 DA semi-iPN graft indicated excellent 
crosslinking and a corollary increase in burst pressure. The improved network formation 
and burst pressure of the DA 600 semi-IPN graft is likely due to the increased reactivity 
of the acrylate and higher molecular weight of the silicone macromer. Following heat 
treatment, the 10/90 DA 600 semi-IPN graft also exhibited the lowest storage modulus 
drop of all the thin grafts, Figure 3.3c, as well as most significant microphase separation 
and highest ordered soft segment crystallinity in its DSC thermogram, Figure 3.4. 
Finally, the degree of fiber fusion of the 10/90 PDMS DA 600 grafts following heat 
treatment appeared to be more similar to Carbothane

 which had minimal effects on 
biomechanical properties, Figure 3.2. As a result, the graft exhibited improved 
biomechanical properties as compared to its as-spun counterpart and the Carbothane

 
control. Overall, the increased compliance of the semi-IPN grafts was attributed to the 
silicone macromer disrupting soft segment crystallinity of the polyurethane, as described 
above. Indeed, a substantial decrease in soft segment crystallinity was observed for all 
semi-IPN grafts, Figure 3.4. 
3.3.2.3 Effect of Thickness on Carbothane
®
 Grafts In order to increase the burst 
pressure of the Carbothane
®
 grafts to match saphenous vein values, the graft thickness 
was increased from 0.2 to 0.4 mm. Our laboratory has previously demonstrated that 
increasing graft thickness via longer electrospinning times can be effectively used to 
enhance burst pressure.
528
 Increased thickness of the Carbothane
®
 grafts resulted in a 
modest increase in burst pressure from 1190 ± 100 to 1330 ± 70 mm Hg and decrease in 
compliance from 3.8 ± 1.0 to 3.2 ± 0.1 %/mmHg x 10
-4
. Initial 12 hour heat treatment of 
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0.4 mm thick Carbothane
®
 specimens produced no changes in graft properties or DMA 
plots (results not shown) indicating longer heat treatment times were needed. Increasing 
the duration of heat treatment to 24 hours increased the compliance (5.1 ± 0.5 %/mmHg 
x 10
-4
) and burst pressure (2260 ± 160 mm Hg) of Carbothane
®
 grafts to values that 
exceeded reported autologous vein properties (saphenous vein compliance: 4.4 ± 0.8 
%/mmHg x 10
-4
 
557
 and burst pressure: 1680 ± 307 mmHg 
558
). Additional heat treatment 
times (48 and 72 hours) did not result in additional improvements in graft biomechanical 
properties (data not shown). 
3.3.2.4 Graft Performance under Physiological Conditions The DMA storage 
modulus plots of the grafts displayed thermal transitions between 30ºC and 40ºC. 
Therefore, it is reasonable to assume that the performance of the grafts under standard 
testing temperature of 25ºC would differ from physiological conditions (37ºC). To 
address this issue, the biomechanical properties of the most promising grafts, 
Carbothane
®
 (0.4 mm thickness) and 10/90 PDMS DA 600 (0.2 mm thickness), were 
equilibrated in water at 37ºC overnight and then tested in a warm room that was held at a 
constant 37°C and 100% relative humidity. The results were then compared with 
previous results obtained under standard laboratory conditions (20°C, ~50% humidity).  
As-spun grafts of both materials were found to exhibit substantial increases in 
compliance, Figure 3.5, after equilibration in water and testing at 37ºC. The increase in 
compliance was attributed to partial melting of the crystalline soft segment, as described 
above with heat treatment. Interestingly, this almost doubling of compliance at 37ºC was 
not accompanied by a significant change in burst pressure as observed with grafts after 
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heat treatment. Both sets of heat-treated grafts displayed large decreases in burst pressure 
at physiological conditions with more modest increases in compliance. The large 
increase in burst pressure of heat-treated grafts observed at 20ºC (Carbothane
®
: 2260 vs 
1330 mm Hg; semi-IPN: 2360 vs 2070 mm Hg) is likely due to a combination of 
polymer morphology and increased fusions. Given that testing under physiological 
conditions did not significantly alter fiber architecture, the decrease in heat-treated graft 
burst pressures at 37°C was attributed to changes in polymer morphology. Specifically, 
we hypothesized that a further reduction of the soft segment crystallinity (Tm = 36 ± 1°C) 
occurred during incubation at 37º which caused the observed decrease in graft burst 
pressures. The less substantial decrease in the semi-IPN could then be attributed to the 
added reinforcement of the silicone network and the increased melting temperature of the 
soft segment in the semi-IPN (45 ± 1, 56 ± 2°C).  Overall, the improved compliance of 
both grafts under the more physiological conditions while maintaining acceptable bust 
pressures suggests favorable performance during implantation may be expected. Based 
on the established correlation with compliance and 5 year patency rates from previous in 
vivo studies, these Carbothane
®
 and 10/90 PDMS DMA 380 grafts are expected to 
exceed previous graft options, Figure 3.6.
512
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Figure 3.5. (A) Compliance and (B) burst pressures of 0.4 mm Carbothane
®
 and 0.2 mm  
10/90 PDMS DA 600 grafts testing at 20°C (room temperature) and 37°C (body 
temperature); 
Ɨdata taken from previous in vivo saphenous vein data from literature; 
*p< . 5 from   °C. 
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Figure 3.6. Projected patency rates of heat treated 0.4 mm thick Carbothane
®
 and 
0.2 mm 10/90 PDMS DA600 semi-IPN grafts based on past linear relationship observed 
in previous in vivo data.
512
 The patency data for the different grafting materials used in 
the femoro-popliteal position used in this study were obtained from several recent large 
studies.   
 
 
 
3.3.4 Confirmation of Crosslinking in Semi-IPN Grafts It can be expected that 
the presence of the silicone macromers in the as-spun grafts could potentially increase 
graft compliance but never improve burst pressure over pure Carbothane grafts due to 
hydrogen bond disruption. Initial testing had demonstrated this effect to be true with all 
grafts containing the PDMS DMA 380 macromer but the DA 600 macromer showed 
only improvements.  Further investigation into the effects on the microphase 
morphology within the as-spun graft indicated higher order crystalline domains existed 
in the as-spun PDMS DA 600 system than Carbothane
®
 despite the lack of heat 
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treatment to crosslink the macromers, Figure 3.7. It is expected that the additional 
energy provided by the fiber jet stretching during the electrospinning process allows for 
premature radical initiation of the acrylate group. As a result, the PDMS DA macromer 
crosslinks while still in solution and in transit to collection on the rotating mandrel. This 
allows for formation of crystalline domains of sizes similar to the methacrylate based 
semi-IPNs but on a higher order. Results correlate with the improved biomechanical 
properties of PDMS DA 600 reported earlier. Heat treatment of the PDMS DA 600 then 
shows a sharper Tg around -30°C than the as spun graft as well as an additional 
endotherm at close to 60°C which suggests further crystallization of the soft segment is 
permitted.  The effect on microphase morphology of the heat treated semi-IPN graft was 
then translated again to even better biomechanical properties. 
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Figure 3.7. DSC thermograms (first scan) of 0.2 mm thick electrospun Carbothane
® 
and 
10/90 PDMS DA 600 grafts before and after heat treatment (12 hours, 50°C) 
 
 
NMR spectroscopy was then utilized to confirm crosslinking of the PDMS 
macromers. Peaks characteristic of the silicone groups within both macromers were 
identified in their respective spectra as well as peaks specifically assigned to 
methacrylate and acrylate end groups for the PDMS DMA and DA macromers 
respectively, Figure 3.8. Spectra from Carbothane
®
 grafts identified peaks characteristic 
of the poly(carbonate urethane) (PCU) that go unchanged following heat treatment, 
Figure 3.9. 
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Figure 3.8. 
H
NMR spectra of PDMS DMA 380 and PDMS DA 600 macromers 
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Figure 3.9 
H
NMR spectra of Carbothane
®
 grafts before and after heat treatment 
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The 10/90 PDMS DMA 380 grafts compared to 20/80 grafts show a clear 
distinction in their NMR spectra following heat treatment due to differences in degree of 
crosslinking of the macromers with increases in concentration, Figure 3.10-3.11. While 
the 20/80 grafts exhibit full crosslinking with losses of the silicone and end group peaks, 
the 10/90 spectra still contained soluble unreacted macromers which are present after 
heat treatment.  
Despite lack of heat treatment on the 10/90 PDMS DA 600 grafts, their 
biomechanical properties still exhibited enhanced biomechanical properties over 
Carbothane
®
 grafts suggesting the macromer is behaving differently during the 
electrospinning process. The NMR spectra of the as spun grafts, in addition to the 
expected effect on the heat treated samples, shows no evidence of the acrylate end 
groups but still a minor presence of the silicone groups from the macromer, Figure 3.12. 
The results suggest that the PDMS DA 600 macromer could potentially be forming a 
crosslinked network prior to electrospun fiber collection which affects biomechanical 
properties. The silicone peak could potentially be attributed to remaining unreacted 
macromer and/or silicone impurities which remains soluble for NMR spectroscopic 
analysis. 
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Figure 3.10. 
H
NMR spectra of electrospun 10/90 PDMS DMA 380 grafts before and 
after heat treatment (12 hours, 50°C) 
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Figure 3.11. 
H
NMR spectra of electrospun 20/80 PDMS DMA 380 grafts before and 
after heat treatment (12 hours, 50°C) 
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Figure 3.12. 
H
NMR spectra of electrospun 10/90 PDMS DA 600 grafts before and after 
heat treatment (12 hours, 50°C) 
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3.4 Conclusions 
Carbothane
®
 electrospun grafts displayed morphological changes after heat 
treatment that improved graft compliance and burst pressure values beyond previously 
reported autologous vein properties. The range of biomechanical properties of the PCU 
grafts was then expanded with the incorporation of a silicone network. Biomechanical 
properties of the most promising grafts were then assessed under physiological 
conditions. Although the graft burst pressure dropped significantly due to disruption of 
soft segment crystallization, the values remained comparable to autologous veins. 
Compliance values for both grafts showed additional improvements at 37ºC. Given the 
known correlation of graft compliance and patency, the improved compliance of both the 
heat-treated Carbothane
®
 and the 10/90 PDMS semi-IPN grafts provide promising 
alternatives to current synthetic grafts and autologous veins as arterial replacements.  
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CHAPTER IV  
INVESTIGATION OF EFFECT OF POLYURETHANE CHEMISTRY ON 
BIOSTABILITY OF COMPOSITE VASCULAR GRAFTS 
 
4.1 Introduction 
When considering the need for long term implantation success, graft biomechanical 
properties make up only half of the functional requirements in a vascular graft design. 
The other is the ability to maintain the graft’s performance over time, specifically in 
regard to predicting and optimizing the biostability of the SPU(s) selected.  SPUs have 
been modified over time to meet design requirements including the need for more 
biostable formulations. The first generation of polyurethanes incorporated a polyester 
based soft segment which was later found to be susceptible to rapid hydrolysis.
42,559
 
PEUs, expected to be more resistant to hydrolytic degradation,
194
 were then developed to 
provide superior biostability; however these materials showed substantial surface and 
full thickness cracking as a result of soft segment chain scission and crosslinking.
258
 The 
failure mechanism of these devices was attributed to metal ion-induced accelerated 
oxidative (MIO) degradation,
560
 which makes them more likely to fail via environmental 
stress cracking (ESC).
261,561
  
In addition to MIO degradation, the immunological response to foreign body 
materials has been cited as a pathway for polyurethane degradation,
562
 where 
polyurethane materials are still shown to degrade in vivo without the presence of 
metals.
563
 A rigorous investigation by Henson suggests macrophages and foreign body 
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giant cells release a multitude of enzymes, acids, and reactive oxygen intermediates 
(ROIs) during phagocytosis.
564,565
 Previous in vivo and in vitro work has demonstrated 
oxidative attack to be the more dominant mechanism
261,273
 over enzymatic 
degradation.
566
 PCUs based on polycarbonate diols were synthesized as a new option for 
biostable SPUs that still result in favorable microphase separation and mechanical 
properties.
567,568
 These PCUs have been evaluated as an alternative to PEUs with 
increased biostability and supported by initial in vitro and in vivo studies demonstrating 
improved resistance to oxidative attack.
2,9,27,36-38
 In addition, this new line of SPUs are 
less susceptible to ESC given an observed reduction in the depth of degradation
16,30,39
 
that was attributed to the lower permeability of polycarbonate to oxygen, water, and 
hydrogen peroxide.
569
 Despite initial successes indicating enhanced biostability of PCUs, 
the materials are still susceptible to oxidative degradation. Thus additional attempts have 
been made to further improve PCU’s resistance to oxidation.  
New PCU formulations were created to further enhance oxidative stability, 
specifically by reducing the probability of chain scission via two methods, silicone 
modification and/or reduction of soft segment. Both of these strategies are well 
supported by similar attempts to improve PEU biostability. Previous studies have shown 
that covalently bonding silicone to polyurethanes has improved the resistance of SPUs to 
both in vitro and in vivo biodegradation as well as reducing the effect of MIO and 
ESC.
25,42,43
 Reduction of soft segment ether content in the harder Pellethane

 and 
Elasthane™ grades also resulted in improved oxidative resistance.570 The increase in 
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oxidative resistance is attributed to the decrease in available α-methylene carbons 
adjacent to the ether linkage.
568
 
Validation of the increase biostability of these new formulations remains 
challenging given the length of time necessary to show statistically significant 
degradation using animal models. Accelerated in vitro testing remains a valuable asset in 
predicting long-term biostability of SPUs using relatively short term experiments with 
the caveat that the in vitro testing accurately reproduces the clinical findings. In vitro-in 
vivo correlations of polyurethane degradation suggests that oxidative degradation is the 
dominant mechanisms leading to device failure. Numerous studies predicting the 
oxidative stability of SPUs have been conducted with a variety of methods trying to 
simulate or provide correlations to physiological degradation rates in vivo. The quantity 
of potential hydrogen peroxide molecules, hydroxyl radicals, and superoxide anions 
released during phagocytosis has been previously approximated with in vitro testing.
571
 
Various concentrations of hydrogen peroxide have been explored with some or no metal 
ions to provide an accelerated in vitro environment.
282,572-574
 The most common of these 
compositions includes a 0.1 M concentration of cobalt (II) chloride (CoCl2) and 20% 
hydrogen peroxide (H2O2) held at 37°C.
261,276,575
 The accelerated system has also been 
reported to provide a strong correlation between the in vitro treatment and in vivo results, 
where 24 days in the CoCl2/H2O2 medium approximated 1 year of implantation for select 
polyurethane compositions.
273
 Alternatively, the ISO 10993-13 (1998) standard for the 
evaluation of medical devices suggests the incubation of materials in a 3% H2O2 solution 
at 37°C as a method to simulate real time oxidative degradation of biomaterials. To the 
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best of our knowledge, the oxidative stability testing of commercially available 
segmented SPUs through the strict use of 3% H2O2 without metal ions has been very 
limited within the literature.
563
 Previous studies look to maintain approximate 
physiological levels but also incorporate the metal ion to simulate the effects of different 
pacemaker lead metals.
576-579
 Despite individual representation within the literature, a 
more comprehensive comparative study between the proposed physiological rate and 
accelerated in vitro treatments is needed to evaluate the methods for predictability of 
performance in vivo. 
The present study compares the accelerated in vitro cobalt (II) chloride and 
concentrated hydrogen peroxide system with the 3% H2O2 in vitro system. Effects on the 
oxidative stability from silicone modification of PCUs and soft segment content 
reduction were examined in both the accelerated and 3% H2O2 systems. Changes in the 
surface chemistry and morphology of the PCUs were monitored using ATR-FTIR 
spectroscopy and SEM respectively. Effects on the bulk of the material were examined 
by tracking molecular weight and uniaxial tensile property changes using gel permeation 
chromatography (GPC) and tensile testing. Results from the present study were then 
compared with previous in vivo studies to predict the oxidative degradation profile of 
each material. Relative percent changes in levels of hydrogen peroxide content in the 
degradation media were calculated using Iodometric titration to determine ROI 
production. Finally, the predictive capabilities of each test based on changes in peroxide 
content and comparison to in vivo degradation results were evaluated for use in future 
oxidative stability studies. 
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4.2 Materials and Methods 
4.2.1 Materials Commercially available poly(carbonate urethanes) PCUs 
Bionate
®
 80A PCU, Bionate
®
 75D PCU, Bionate
®
 II 80A PCU, Bionate
®
 II 75D PCU, 
CarboSil
®
 20 80A silicone-modified thermoplastic poly(carbonate urethane) (TSPCU), 
and CarboSil
®
 20 55D TSPCU were synthesized by DSM Biomedical (Berkeley, CA). 
Resins were dried for approximately 4 hours at 100ºC prior to melt extrusion into films 
200-3   μm thick by DSM Biomedical. Films were cut into 1.5 cm x 4 cm rectangular 
specimens and dog bones according to ASTM standard 1708D with the gauge length 
parallel to the direction of film extrusion. Rectangular and dog bone specimens were 
annealed in sealed vials at 90°C for 24 hours followed by slow cooling prior to in vitro 
biodegradation. Cobalt (II) chloride hexahydrate (CoCl2), N,N’-dimethylformamide 
(DMF), lithium bromide (LiBr), potassium iodide (KI), sulfuric acid (H2SO4), sodium 
thiosulfate (Na2S2O3), ammonium hydroxide (NH4OH), ammonium nitrate (NH4NO3), 
and ammonium heptamolybdate ((NH4)6Mo7O24), and starch solution were purchased 
and used as received from Sigma Aldrich (Milwaukee, WI). H2O2 at concentrations of 
3% and 30% (w/v) were purchased and used as received from VWR International. 
4.2.2 In Vitro Biodegradation All in vitro experiments were conducted at 37°C 
on unstrained films (n=5) in two different oxidative solutions: accelerated oxidative and 
physiological approximated treatment based on the ISO 10993-13 standard.  An 
oxidative solution of 0.1 M CoCl2 and 20% H2O2 was used to treat the PCUs at an 
accelerated rate for 36 days with solution changes every 3 days to maintain a relatively 
constant concentration of radicals.  PCUs treated according to ISO standard 10993-13 
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were subject to a 3% H2O2 solution with weekly media changes for 12 months. The 3% 
method did not include any concentration of metal ions to catalyze hydrogen peroxide 
decomposition. The films were rinsed with reverse osmosis water and vacuum dried 
overnight at ambient temperatures before characterization. 
4.2.3 Characterization 
4.2.3.1 Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy 
(ATR-FTIR) Changes in surface chemistry were observed using ATR-FTIR 
spectroscopy. Spectra were recorded with a Bruker ALPHA FTIR spectrometer 
equipped with a 45° germanium crystal (Billerica, MA). All spectra were normalized to 
the 1600 cm
-1
 peak corresponding to the C=C bond stretch of the aromatic ring in the 
PCU hard segment. Changes in soft segment content were quantified by monitoring 
differences in the 1256 cm
-1
 peak height (C-O of soft segment carbonate) relative to the 
internal reference peak using the equation below:   
                      
       
     
     , 
where I = 1256 cm
-1
 peak height relative to the 1600 cm
-1
 peak height. 
4.2.3.2 Uniaxial Tensile Testing Following cleaning and drying, dog bone 
specimens were strained at a rate of 100%/min to failure using an Instron 3345 equipped 
with air pneumatic grips (Norwood, MA). Tensile stress was calculated and plotted 
versus percent elongation. Initial 2% secant modulus, tensile strength, and ultimate 
elongation were all calculated from the resultant stress vs. strain plots. 
4.2.3.3 Gel Permeation Chromatography (GPC) Changes in molecular weight 
and molecular weight distribution were monitored using GPC. Briefly, specimens were 
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dissolved in a 0.1 M LiBr solution of DMF at approximately 5 mg/mL concentrations. 
GPC solutions were incubated at 70°C for 6 hours with mild periodic agitation to ensure 
full specimen dissolution and elimination of hydrogen bonding. Specimens were eluted 
through a GPC Max (Viscotek, Malvern, PA) equipped with two Phenomenex columns 
with pores of 10
3
 and 10
5
 Å in diameter. DMF with 0.05 M LiBr at a flow rate of 1.0 
mL/min at 80°C was used as an eluent and refractive index response was used as 
detection. OmniSEC software was calibrated using a set of conventional narrow 
polystyrene standards with molecular weights of 10, 50, 100, 300, 500, 800, 1000 kDa 
(Agilent Technologies, Santa Clara, CA). Weight average molecular weight ( MW  ) and 
polydispersity index (PDI) were calculated from chromatograms of annealed untreated 
and degraded specimens from accelerated and 3% H2O2 in vitro treatments. MW  and 
PDI values were reported as average ± standard deviation. 
4.2.3.4 Scanning Electron Microscopy (SEM) SEM was used to examine the 
surfaces of unstrained and strained to failure PCUs before and after in vitro treatment. 
Surface morphology of unstrained and strained to failure specimens were observed using 
a JEOL JCM-5000 NeoScope scanning electron microscope (SEM). An acceleration 
voltage of 5 kV and working distance of 8 mm were used. A gold layer of approximately 
200-300 Å was deposited on all specimens prior to imaging to increase conductivity.  
Unstrained specimens were harvested from annealed untreated and degraded rectangular 
films. Strained to failure specimens were taken from fractured tensile testing specimens. 
Images were taken at magnitudes of 500X and 2000X to highlight both low and high 
resolution surface topography features. 
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4.2.4 Monitoring Peroxide Levels Percent hydrogen peroxide was calculated 
using a basic iodometric titration process performed in a previous oxidation study to 
confirm changes in peroxide content.
574
 KI solution was prepared in 1% (w/v) 
concentration with deionized water. Ammonium molybdate solution was prepared by 
dissolving 9 grams of (NH4)6Mo7O24 and 24 grams of NH4NO3 in 10 mL of 6 N NH4OH 
and 100 mL of deionized water. H2SO4 solution was prepared in a 20% (v/v) 
concentration with deionized water. Finally 0.2 N sodium thiosulfate solution was 
prepared by dissolving 25 g Na2S2O3 in 1 L of deionized water.  
Approximately 1 mL of each in vitro treatment solution was taken prior to a 
scheduled solution change and weighed to the nearest 0.1 mg. The samples were added 
to a solution of Na2S2O3, KI, and DI water of 10, 10, and 50 mL respectively. Two drops 
of ammonium molybdate solution were then added. The solution was titrated with 0.2 N 
Na2S4O6 until the liquid appeared to be a faint yellow color, followed by an addition of 2 
mL of starch solution before the final exact titration with 0.2 N Na2S4O6 solution was 
performed. The process was repeated with water for each sample. Percent hydrogen 
peroxide content was calculated using the following equation: 
       
       (            )
                     
 
The procedure was conducted on oxidative medium with 3, 10, and 20% H2O2 
concentration combined with 0, 0.05, 0.1 and 0.2 M CoCl2 to decompose the peroxide 
into radicals.  Levels of peroxide were calculated at 0, 3 and 7 days. 
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4.2.5 Statistical Analysis A two-tailed student’s T-test was performed to 
determine statistical significance between groups of data. All comparisons were made 
with a 95% confidence interval. (α  . 5) 
 
4.3 Results and Discussion 
 
4.3.1 Initial Characterization All three PCU products were expected to include a 
polycarbonate glycol and similar hard segment chemistries with CarboSil
®
 TSPCU 
products also containing silicone at approximately 20% of the soft segment content, 
Table 4.1. Structural features of all of the PCUs were examined with infrared 
spectroscopy. Characteristic ATR-FTIR spectra of each PCU film prior to treatment are 
shown in Figures 4.1-4.6. The materials all exhibited the same peaks characteristic of 
thermoplastic PCU with the exception of CarboSil
®
 20 80A TSPCU and CarboSil
®
 20 
55D TSPCU samples, which also included peaks assigned to groups within the silicone 
segment, Table 4.2. Soft segment indices were calculated from the ATR-FTIR spectra of 
the PCUs to determine changes in soft segment content. The 1600 cm
-1
 peak of all PCUs 
was assigned to the C=C stretch of the aromatic ring within the hard segment based on 
previous studies observing MDI-based polyurethanes.
544
 The aromatic ring band also 
served as the internal reference peak, which all spectra peak heights of interest were 
normalized.  
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Table 4.1. Characterization of polyurethanes 
Material Hard Segment Soft Segment Hardness Grade 
Bionate
® 
PCU 
MDI/BDO Polycarbonate Glycol 
80A 
75D 
Bionate
®
 II 
PCU 
MDI/BDO Polycarbonate Glycol 
80A 
75D 
CarboSil
®
 
TSPCU 
MDI/BDO Polycarbonate Glycol/Silicone Diol 
20 80A 
20 55D 
MDI = methylene di(p-phenyl isocyanate); BDO = butane diol 
 
 
Table 4.2. ATR-FTIR spectral assignments 
Wavenumber (cm
-1
) Spectral Assignment 
1742 C=O Carbonate Nonbonded 
1724 C=O Carbonate H-bonded 
1705 C=O Urethane H-bonded 
1600 C=C Benzene Ring 
1534 C-N + N-H Amide 
1415 C-C Benzene Ring 
1313 C-N + N-H 
1256 C-O-C of Carbonate 
1232 C-N 
1115 C-O 
803 Si-CH3 of Silicone 
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Figure 4.1. ATR-FTIR spectra of untreated Bionate
®
 80A specimens compared to specimens after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment (0.1M CoCl2/20% H2O2 at 37°C) 
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Figure 4.2. ATR-FTIR spectra of untreated Bionate
®
 75D specimens compared to specimens after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment (0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.3. ATR-FTIR spectra of untreated Bionate
®
 II 80A specimens compared to specimens after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment (0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.4. ATR-FTIR spectra of untreated Bionate
®
 II 75D specimens compared to specimens after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment (0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.5. ATR-FTIR spectra of untreated CarboSil
®
 20 80A specimens compared to specimens after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment (0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.6. ATR-FTIR spectra of untreated CarboSil
®
 20 55D specimens compared to specimens after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment (0.1 M CoCl2/20% H2O2 at 37°C) 
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As expected, the soft segment indices of all soft 80A hardness grade materials were 
found to be significantly higher than their harder grade components, Table 4.3. This 
indicated an increased presence of soft segment carbonate linkages on the surface of the 
annealed extruded films. Bionate
®
 II 80A PCU has a polycarbonate diol different from 
the standard macroglycol used in Bionate
®
 80A PCU. While no additional peaks were 
visible in Bionate
®
 II 80A PCU, the soft segment carbonate index was found to be 
higher in the new PCU compared to Bionate
®
 80A PCU. The difference in chemistry is 
presumed to allow for greater enrichment of the soft segment in Bionate
® 
II 80A PCU 
following melt extrusion processing. While the result is highly pronounced in the soft 
grade material, no significant difference is reported between the hard grade PCUs. 
CarboSil
®
 20 80A TSPCU exhibited a lower soft segment carbonate index likely due to 
the introduction of silicone glycol to the soft segment. 
 
Table 4.3. Soft segment loss of PCUs after 12 months in vitro treatment 
(3% H2O2 at 37°C) and accelerated in vitro treatment (0.1 M CoCl2/20% H2O2 at 37°C) 
  Untreated 12 Months 3% H2O2 36 Days Accelerated 
  
1256/ 
1600 cm
-1 
1256/ 
1600 cm
-1 
Percent 
Change 
1256/ 
1600 cm
-1 
Percent 
Change 
Bionate
®
 
PCU 
80A 9.1 ± 0.2 8.5 ± 0.2
a 
-7 ± 2% 5.2 ± 0.7
a
 -27 ± 10% 
75D 3.1 ± 0.1 3.0 ± 0.1 -1 ± 1% 2.4 ± 0.1
a 
-16 ± 1% 
Bionate
®
 II 
PCU 
80A 9.3 ± 0.3 11.0 ± 0.5
a 
+18 ± 5% 5.7 ± 0.2
a 
-34 ± 3% 
75D 3.0 ± 0.1 2.9 ± 0.1
a 
-2 ± 1% 2.3 ± 0.1
a 
-21 ± 2% 
CarboSil
®
 
TSPCU 
20 80A 6.5 ± 0.1 6.6 ± 0.2 +1 ± 3% 4.1 ± 0.3
a 
-27 ± 9% 
20 55D 4.0 ± 0.1 4.0 ± 0.1
a 
+2 ± 1% 3.1 ± 0.2
a 
-20 ± 6% 
(average ± standard deviation; n=10; 
a
p<0.05 from untreated) 
 
Molecular weights calculated with GPC were found to be fairly similar between the 
hard soft grade material with the exception of Bionate
®
 II 80A PCU. Bionate
®
 II 80A 
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material had a substantially higher molecular weight than its 75D counterpart as well as 
all of the other PCU materials. The polydispersity index (PDI) was similar indicating 
that the differences in soft segment content and chemistry did not influence the 
molecular weight distribution. No significant differences were observed between the 
untreated Bionate
®
 80A and Bionate
®
 II 80A PCUs despite the differences in soft 
segment composition and molecular weights. However; tensile testing of untreated dog 
bones yielded substantially higher initial secant moduli and lower percent elongation in 
the harder grade materials as expected given the lower soft segment content, Table 4.4. 
The CarboSil
®
 products were found to exhibit lower ultimate tensile strengths and 
ultimate elongations given the presence of the silicone groups within the soft segment.  
Previous research has shown linear silicones to have weaker ultimate tensile strengths 
than TPUs, but remain highly flexible allowing for greater ultimate elongation.
580
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Table 4.4. Uniaxial tensile properties of PCUs before and after 12 months in vitro treatment (3% H2O2 at 37°C) and 
accelerated in vitro treatment (0.1 M CoCl2/20% H2O2 at 37°C) 
 
2% Secant Modulus (MPa) Ultimate Tensile Strength (MPa) Percent Elongation 
Untreated 12 Months 
36 Days 
Accelerated 
Untreated 12 Months 
36 Days 
Accelerated 
Untreated 12 Months 
36 Days 
Accelerated 
Bionate
®
 
PCU 
80A 20 ± 1 19 ± 2 19 ± 1 68 ± 6 55 ± 7
a 
54 ± 2
a
 364 ± 8% 392 ± 25%
a
 367 ± 10% 
75D 670 ± 25 950 ± 79
a 
750 ± 21
a 
47 ± 2 48 ± 4 39 ± 5
a
 184 ± 14% 183 ± 14% 163 ± 30% 
Bionate
®
 II 
PCU 
80A 17 ± 1 19 ± 1 19 ± 1
a
 65 ± 10 64 ± 1 80 ± 5
a 
415 ± 43% 423 ± 18% 417 ± 10% 
75D 1106 ± 68 1291 ± 24
a 
1049 ± 41 50 ± 6 52 ± 7 43 ± 7 213 ± 26% 169 ± 10%
a
 181 ± 20% 
CarboSil
®
 
TSPCU 
20 80A 21 ± 1 22 ± 1 23 ± 2
a 
46 ± 3 41 ± 3
a
 49 ± 4 359 ± 25% 393 ± 19% 391 ± 20%
a 
20 55D 135 ± 6 125 ± 6
a 
137 ± 2 40 ± 3 38 ± 1 39 ± 3 302 ± 17% 304 ± 9% 275 ± 20% 
(average ± standard deviation; n=5; 
a
p<0.05 from untreated) 
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4.3.2 In Vitro Biodegradation 
4.3.2.1  Accelerated In Vitro Treatment A 0.1 M CoCl2/20% H2O2 solution was 
used to accelerate oxidative degradation of the PCUs by generating higher 
concentrations of ROIs. The cobalt ions are expected to rapidly decompose the hydrogen 
peroxide molecules via the Haber-Weiss reaction. 
190
 The increased concentration of 
ROIs within the degradation medium was expected to help simulate a longer degradation 
period in vivo.  Results after 24 days have been projected to resemble approximately 12 
months of in vivo implantation, as indicated by previous correlation studies of similar 
materials.
273
 The current study’s endpoint of 36 days of in vitro treatment is therefore 
expected to simulate even longer implantation periods. 
Greater soft segment loss was observed in all of the softer grade materials in the 
accelerated medium due to the higher probability of soft segment chain scission at the 
more prevalent carbonate linkages, Table 4.3. Briefly, ROIs abstract the α-methylene 
carbon within the soft segment leaving an open radical along with the backbone. The 
radical then reacts with a hydroxyl to form a hemiacetal which can oxidize into an ester.  
Chain scission results from acid hydrolysis of the ester and soft segment loss can be 
attributed to solubilization of low MW  soft segment species.
190
 In the accelerated 
medium, Bionate
®
 80A PCU displayed approximately 27.5% soft segment loss at the 
surface following 36 days accelerated in vitro treatment. The PCU soft segment losses 
were found to be lower than expected values given previous 12 month in vivo data which 
showed a 32% soft segment loss using the same peak height analysis method.
273
 
Previous in vivo results did show the silicone modified PCU to exhibit a greater 
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oxidative biostability under real physiological conditions but those were not seen with 
the accelerated treatment, Figure 4.5, Table 4.3. Bionate
®
 II 80A PCU exhibited a 
slightly greater soft segment carbonate loss in the accelerated medium though results 
were not statistically significant, Figure 4.1, Figure 4.3, Table 4.3. All hard grade 
PCUs also displayed soft segment loss but less than their softer grade counterparts in the 
accelerated medium. No significant difference was found between the three PCUs 
themselves, Table 4.3. The lack of separation between the three materials is likely due to 
the decreased soft segment content acting as the dominant variable.  
All materials exhibited evidence of surface crosslinking with emergence of the 1174 
cm
-1
 peak following 36 days accelerated in vitro treatment, Figures 4.1-4.6, indicating 
the presence of branched ethers.
575
 Similar results were observed in previous in vivo 
studies where both Bionate
®
 80A PCU and CarboSil
®
 20 80A TSPCU exhibited ATR-
FTIR spectra with the presence of the 1174 cm
-1
 peak.
273,581
 The result has previously 
been attributed to the attraction of two free radicals on the soft segment chain resulting 
in crosslinking of the soft segment before progression into hydrolysis chain scission.  
In addition to soft segment changes, the presence of the aromatic amine group in all 
the materials, as shown by the emerging 1650 cm
-1
 peak, indicates that the PCUs also 
experienced hard segment degradation, Figures 4.1-4.6.
261
 Briefly, the α-methylene 
carbon next to the urethane group in the PCUs is again abstracted from the hard segment 
and the same proposed progression into chain scission is expected to occur, leaving free 
aromatic amines.
261
 Previous in vivo studies also confirmed hard segment degradation in 
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both Bionate
®
 80A PCU and CarboSil
®
 20 80A TSPCU which again is in agreement 
with the accelerated treatment.  
In the accelerated medium, all 80A specimens exhibited greater MW  loss than their  
harder grade counterparts with the greatest separation occurring between the two 
CarboSil
®
 materials, Table 4.5. However; the percent molecular weight losses were 
minimal compared to surface soft segment content losses indicating that the bulk of all 
the materials were retained following 36 days of accelerated treatment. 
 
 
Table 4.5. Molecular weight changes of PCUs after 12 months in vitro 
treatment (3% H2O2 at 37°C) and accelerated in vitro treatment 
(0.1 M CoCl2/20% H2O2 at 37°C) 
  12 Months 3% H2O2 36 Days Accelerated 
  % MW  Change % MW   Change 
Bionate
®
 
PCU 
80A -9 ± 3%
a 
-12 ± 6%
a 
75D -2 ± 2% -8 ± 3%
a 
Bionate
®
 II 
PCU 
80A -2 ± 3% -9 ± 6%
a 
75D -19 ± 4%
a 
-5 ± 5% 
CarboSil
®
 
TSPCU 
20 80A -8 ± 3%
a 
-15 ± 5%
a 
20 55D -11 ± 3%
a 
-6 ± 6% 
(average ± standard deviation; n=10; 
a
p<0.05 from untreated) 
 
All materials retained their uniaxial tensile properties following 36 days accelerated 
in vitro treatment. Bionate
®
 80A and 75D PCU grades, exhibited a small loss in ultimate 
tensile strength, and Bionate
®
 II 80A PCU exhibited increases in both initial secant 
modulus and ultimate tensile strength, Table 4.4. These increases in tensile properties 
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were attributed to possible reorganization of the hard domains as a result of prolonged 
incubation in solution. 
Bionate
®
 80A PCU exhibited the highest density of pitting among all 6 materials 
despite its spectral changes, while all other Bionate
®
 materials showed similar densities, 
Figures 4.7-4.12. The differences in results for Bionate
®
 80A PCU could be attributed to 
the limited depth of the ATR-FTIR instrument when monitoring affected SPU depth. 
CarboSil
®
 products exhibited a reduced pitting density likely due to the presence of 
silicone on the surface. Decreases in pit density of the TSPCU have also been previously 
demonstrated in vivo.
273
 Despite evidence of surface degradation in the form of pitting, 
there was no evidence of environmental stress cracking even on the strained-to-failure 
specimens of any of the PCUs in the study.  This is in contrast to PEUs that are subject 
to ESC after accelerated oxidative treatment
261
 and in vivo,
190
 which has been proposed 
as the primary failure mechanisms of these devices upon progression to full thickness 
cracking. 
4.3.2.2 ISO 10993 In Vitro Treatment A second set of samples was subject to a 
mild treatment in a 3% H2O2 solution as per ISO standard 10993-13. The ISO treatment 
was expected to better resemble a more physiological concentration of hydrogen 
peroxide. No metal ion was included within this treatment to encourage decomposition 
of the hydrogen peroxide molecules. 
The 12 month 3% H2O2 sample set of Bionate
®
 80A PCU, was found to only lose 
approximately 7.2% of its surface soft segment despite being expected to experience 
more physiological levels of hydrogen peroxide. In addition, it was the only PCU in this 
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study to show soft segment loss despite known losses in other commercially available 
products including CarboSil
®
 20 80A TSPCU.
581
 Despite significant changes in the 
accelerated medium, Bionate
®
 II 80A PCU was found to exhibit a substantial increase in 
soft segment content at the surface following 12 months of treatment in the 3% H2O2 
system. The changes are potentially attributed to a consistent 12 month incubation 
causing more soft segment to migrate to the surface. While the PCUs have exhibited 
surface crosslinking in the accelerated medium and following explantation, no 1174 cm
-1
 
peak was detected in any of the 6 materials following 12 months treatment in 3% H2O2. 
Similar to the crosslinking, no evidence of hard segment degradation was seen in any of  
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Figure 4.7. Scanning electron micrographs of unstrained and strained to failure 
Bionate
®
 80A PCU specimens showing surface damage after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment 
(0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.8. Scanning electron micrographs of unstrained and strained to failure 
Bionate
®
 75D PCU specimens showing surface damage after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment 
(0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.9. Scanning electron micrographs of unstrained and strained to failure 
Bionate
®
 II 80A specimens showing surface damage after 12 months in vitro treatment 
(3% H2O2 at 37°C) and 36 days accelerated in vitro treatment 
(0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.10. Scanning electron micrographs of unstrained and strained to failure 
Bionate
®
 II 75D specimens showing surface damage after 12 months in vitro treatment 
(3% H2O2 at 37°C) and 36 days accelerated in vitro treatment 
(0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.11. Scanning electron micrographs of unstrained and strained to failure 
CarboSil
®
 20 80A TSPCU specimens showing surface damage after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment 
(0.1 M CoCl2/20% H2O2 at 37°C) 
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Figure 4.12. Scanning electron micrographs of unstrained and strained to failure 
CarboSil
®
 20 55D TSPCU specimens showing surface damage after 12 months in vitro 
treatment (3% H2O2 at 37°C) and 36 days accelerated in vitro treatment 
(0.1 M CoCl2/20% H2O2 at 37°C) 
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the materials following 12 months treatment in the 3% H2O2 solution, which falls in line 
with the minor soft segment loss. 
Bionate
®
 80A PCU exhibited a minor loss in molecular weight similar to its soft 
segment loss indicating an evenly distributed chain scission throughout the material, 
Table 4.5. Bionate
®
 II 75D PCU exhibited the greatest molecular weight loss after 12 
months despite its consistent molecular weight in the accelerated medium and the 
observed retention of surface chemistry. Though not as severe as the aforementioned 
PCU, CarboSil
®
 20 55D TSPCU also showed a greater MW  loss in the 3% H2O2 
medium despite no change in MW  after accelerated treatment. The 80A grade TSPCU 
did exhibit a lower molecular weight loss though no difference was observed between 
CarboSil
®
 20 80A and Bionate
®
 80A grades. Finally, a consistent PDI observed within 
all six PCUs following 12 months 3% H2O2 treatment suggests that the bulk of the 
materials are changing at the same rate as the surface.  
Materials again retained the majority of their uniaxial tensile properties.  The 
ultimate tensile strength of the standard PCU was found to statistically decrease over 12 
months which correlates with the small molecular weight changes observed. CarboSil
® 
20 80A TSPCU was also found to exhibit a small decrease in uniaxial tensile strength, 
but no changes were observed in the other material properties. Increases in initial secant 
modulus were observed in all 3 hard grade PCUs which suggests the materials may 
increase in stiffness following 12 months incubation at body temperature, not due to 
oxidative degradation. 
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No significant evidence of erosion was observed on the surface of the PCU 
materials following 12 months 3% H2O2 in vitro treatment. Bionate
®
 80A PCU exhibits 
no additional surface features not seen on the untreated specimens despite being the only 
PCU to indicate soft segment loss after exposure to the 3% H2O2 solution. The lack of 
differences in the surface morphology of the PCUs following 12 months incubation does 
not correlated with previously observed surface pitting after 12 months in vivo. 
Finally, it should be noted that while these materials are subject to only a 3% 
H2O2 concentration, they are also immersed in a 97% percent water degradation 
medium.  All 6 PCUs were demonstrated to be highly stable, both on the surface and 
within the bulk, in this in vitro testing system. Therefore, it has also been shown that 
these commercially available SPUs are highly resistant to hydrolytic degradation within 
the demonstrated time period. 
4.3.3 Peroxide Content Level Iodometric titration was performed on both 
solutions for in vitro treatment to quantify any possible changes in hydrogen peroxide 
levels prior to scheduled solution changes. Levels of H2O2 in solutions of 3, 10, and 20% 
w/v concentration with 0, 0.025, 0.1 and 0.2 M CoCl2 content were monitored after 3 
and 7 days to determine ROI production, Table 4.6. Percent H2O2 lost over incubation 
time increased with higher ratios of CoCl2 to H2O2 concentrations as expected given the 
effect of the Haber-Weiss reaction. 
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Table 4.6. Relative percent changes in H2O2 content following 3 and 7 days incubation 
 
3% H2O2 10% H2O2 20% H2O2 
3 Days 7 Days 3 Days 7 Days 3 Days 7 Days 
No CoCl2 +1 ± 5% +6 ± 3% +7 ± 7% +1 ± 12% -5 ± 7% +1 ± 3% 
0.025 M 
CoCl2 
-42 ± 1%
a 
-52 ± 1%
a 
-14 ± 4%
a 
-13 ± 7%
a 
+1.9 ± 6.9% -1 ± 1% 
0.1 M 
CoCl2 
--- --- -30 ± 7%
a 
-42 ± 3%
a 
-19 ± 3%
a 
 -24 ± 1%
a 
0.2 M 
CoCl2 
--- --- -29 ± 7%
a 
-49 ± 1%
a 
-20 ± 6%
a 
-26 ± 8%
a 
(average ± standard deviation; n=3; 
a
p<0.05 from untreated) 
 
Solutions exposed to varying levels of CoCl2 exhibited significant changes in 
H2O2 content over 3 and 7 days of incubation. Rate of H2O2 decomposition was shown 
to be highly dependent on concentration of CoCl2 and H2O2 within the solution. For all 
solutions with CoCl2 the acceleration effect was far greater within the first 3 days than 
the remainder of the 7 day period where only a small percentage of additional H2O2, if 
any, was lost. This slowing of ROI production is attributed to the initial consumption of 
CoCl2 during the first 3 days leaving a lower concentration of metal ions for the final 4 
days. In addition, increasing CoCl2 concentration was only found to accelerated H2O2 
decomposition at lower levels while doubling from 0.1 to 0.2 M concentrations had no 
significant effect. Overall, the results from the ROI production quantification of the 
accelerated in vitro system in the current study show that relative levels of H2O2 
concentration are kept within an acceptable steady range throughout the full 36 days.  
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No significant changes in H2O2 content were observed in all three solutions with 
no CoCl2 in the degradation media indicating that there is no significant decomposition 
of the molecules during that time period. The lack of change also suggests there were no 
measurable levels of ROIs produced in the solution during that time period. 
Furthermore, no significant ROI presence in the 3% H2O2 solution provides an 
explanation for the lack of degradation evidence in all 6 PCUs following 12 months 
incubation. 
4.3.4 In Vivo Treatment Predictability The disparity between results from the 
accelerated and 3% H2O2 in vitro systems highlights the need for a discussion on the 
predictive efficacy of each test method as it relates to biostability. Iodometric titration 
provided a strong explanation for the difference in the two test methods as only the 
CoCl2 solution produces ROIs. The initiation of oxidation via hydrogen atom abstraction 
cannot be completed without the presence of an oxygen radical.  Therefore, the 3% 
method, which was shown to produce no ROIs during a 7 day incubation period, did not 
expose any of the PCUs to a real physiological environment. The accelerated method 
was the only testing condition to provide results comparable to in vivo data while the 3% 
method could not provide a feasible correlation to physiologic degradation. 
ATR-FTIR spectroscopy has been used previously to track chemical changes in 
PEUs, Bionate
®
 and CarboSil
®
 materials from in vitro and in vivo studies often 
providing useful comparisons between the two.
190,261,581
 The calculated soft segment loss 
of Bionate
®
 80A PCU after 36 days accelerated oxidation does not exceed the 12 month 
data point from previous in vivo data,
273
 but the results are far more significant than the 
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3% H2O2 system.  Furthermore, the degradation rates of these materials were found to be 
far slower after 12 months 3% H2O2 treatment than typical in vivo data.  In addition to 
the lack of soft segment loss seen in all of the PCUs, no additional symptoms of 
substantial degradation were observed including: soft segment crosslinking, hard 
segment degradation, and surface pitting. The difference in surface changes between the 
two test methods can be directly attributed to the disparity in ROI production during the 
incubation periods. In addition, with the exception of molecular weight, all additional 
materials characterization changes within the 3% H2O2 system were attributed more to 
the length of incubation time than to any oxidative degradation effects. The accelerated 
degradation testing was found to exhibit results more indicative of known surface 
oxidative degradation behavior as the media contains ROIs during incubation. It is well 
established that ROI-mediated degradation is limited to the surface of polyurethanes due 
to the high reactivity of these radicals. Specifically, more substantial changes were 
observed in the ATR-FTIR spectra and scanning electron micrographs, while tensile 
testing and GPC analysis show more subtle, if any, changes to the bulk of the materials. 
It is important to note the similarities between the accelerated oxidative system and 
previous in vivo data that indicate surface-specific oxidation occurs but without the ESC 
that caused failure of PEU-based leads. Finally, given that the 3% H2O2 method is an 
aqueous solution, the lack of degradation after 12 months also indicates the hydrolytic 
stability of these PCU materials. 
 
 
 105 
 
4.4 Conclusions 
All materials were found to exhibit signs of oxidative degradation following 36 days 
exposure to the accelerated oxidative environment. Minor changes in molecular weight, 
as indicated by the GPC results and mechanical properties, indicate the bulk properties 
of all materials were retained following accelerated or 3% H2O2 in vitro treatment. 
Furthermore, the lack of cracking seen in all materials following oxidative environment 
exposure suggests that the PCUs will be resistant to environmental stress cracking. Thus, 
these materials are all likely to outlast PEUs in vivo and should be considered as strong 
candidates for biostable medical devices. However; the lack of changes observed on the 
material surfaces in the 12 month group does not correlate with previous in vivo results, 
which suggests the test method does not simulate physiological conditions. The lack of 
ROI production over the 7 day incubation period raises a significant concern over the 
efficacy of the 3% H2O2 test method. Oxidation of PCUs is not expected to be initiated 
without the presence of an oxygen radical. Therefore, it can be concluded that the 3% 
H2O2 method does not simulate an oxidative environment previously demonstrated in 
other in vitro tests but demonstrates the hydrolytic stability of these materials after 12 
months. Based on the comparison between the two tests with previous in vivo results, the 
accelerated metal ion-catalyzed method should remain the recommended choice for 
predicting SPU biostability. 
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CHAPTER V  
DEVELOPMENT OF BIODEGRADABLE POLYURETHANE MATERIAL FOR 
REINFORCING LAYER OF TISSUE ENGINEERING VASCULAR GRAFT 
 
5.1 Introduction  
All design modifications/optimizations up to this point have focused on 
fabricating a long term biostable multilayer graft that properly mimics the behaviors of 
the surrounding tissue. The limitation with this design approach is it eliminates the 
potential to restore the vasoactive function of the reinforcing graft. The design of a tissue 
engineering vascular graft with a biodegradable polyurethane based reinforcing layer 
would provide a strong opportunity to set up for vasoactivity restoration. Fortunately, the 
high tunability of polyurethanes is especially useful in designing biodegradable materials 
as one can readily incorporate biodegradable components into the segmental chemistry. 
Some examples of biodegradable applications of SPUs include wound dressings,
248,582-
588
 abdominal wall replacements,
142,250,589
 gene vector and vaccine delivery,
160,590-598
 
oroantral communication closures,
599
 ophthalmological devices
197
 as well as various 
tissue engineering applications.
487,600-602
 
Linear aliphatic isocyanates such as 1,4-butane diisocyanate (BDI) and 1,6-
hexane diisocyanate (HDI)
603
 are most commonly used in biodegradable polyurethane 
formulations. Lysine  diisocyanate (LDI) has also been investigated with the assumption 
that its lysine-based chemistry will yield safe carboxylic byproducts.
500
 Unfortunately, 
these compounds often have lower tensile strengths (~30 MPa)
604
 than aromatic SPU 
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products such as Biomer™ and Pellethane™ (~50 MPa).605 Despite the promising 
cytocompatibility of these materials along with other linear isocyanates such as 
isophorone diisocyanate (IPDI)
253,606,607
 and  , ’-dicyclohexylmethane diisocyanate 
(H12MDI),
195,608-610
 these aliphatic polyurethanes do not match the mechanical 
properties of their aromatic counterparts.  
In order to generate a resorbable polyurethane with enhanced mechanical 
properties and safe degradation products, novel aromatic and biodegradable isocyanates 
were recently developed by Bezwada Biomedical.
611
 Briefly, several aromatic 
isocyanates were synthesized with amino phenols, amino salicylic acids, and amino 
benzoic acids that are expected to degrade via hydrolysis into non-toxic byproducts.
611
 
DSM Biomedical, in collaboration with Bezwada Biomedical, synthesized a poly(ester 
urethane) (PEsU) with an aromatic hard segment based on glycolic acid and a 
polycaprolactone soft segment to investigate the potential of these novel aromatic PEsU 
for biomedical applications. In this study, we present the initial characterization of this 
PEsU and the accelerated hydrolytic degradation profile after four weeks in vitro. 
 
 
5.2 Materials and Methods 
5.2.1 Materials A commercially available poly(ether urethane urea) (PEUU), 
BioSpan
®
 80A, and the resorbable PEsU were synthesized by DSM Biomedical 
(Berkeley, CA) and supplied in    wt%  and    wt% N,N’-dimethylacetamide (DMAC, 
Sigma Aldrich, Milwaukee, WI) solutions, respectively. PEsU and PEUU films were 
solvent cast from 10 wt% DMAc solutions and dried under vacuum at ambient 
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temperature until all solvent was removed. Specimens of dimensions 30 mm x 5.5 mm x 
0.25 mm were cut from dried films and used in characterization and degradation studies. 
5.2.2 In Vitro Biodegradation PEUU and PEsU specimens (n = 4) were 
immersed in phosphate buffer saline (PBS) or 0.1M sodium hydroxide (NaOH) solution 
to promote hydrolysis at an accelerated rate. Solutions were kept at a constant 37°C with 
mild agitation for up to four weeks. Degradation medium was changed every week and 
specimens removed for characterization. Specimens were rinsed with deionized water 
and dried overnight under vacuum to remove residual water prior to analysis. 
5.2.3 Gravimetric Analysis Gravimetric analysis was performed by weighing 
specimens before immersion and then following cleaning and drying procedures to 
determine mass loss due to erosion. Percent change in mass was calculated for each 
specimen using the equation below: 
%100%
0
0
x
m
mm
Change

 , 
where m = mass of degraded specimen and m0 = initial mass of specimen. 
5.2.4 Chemical Analysis Changes in bulk and surface chemistry were observed 
using transmission and attenuated total reflectance (ATR)-Fourier transform infrared 
(FTIR) spectroscopy, respectively. Transmission-FTIR specimens were prepared by 
dissolving specimens in dilute solutions with DMAC and solution cast onto clean 
potassium bromide (KBr) pellets under vacuum until all solvent was removed. Spectra 
were recorded with a Bruker Tensor 27 FTIR spectrometer (Billerica, MA). ATR-FTIR 
was performed using a PikeTech multi-reflectance ATR Max II (Madison, WI) position 
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at a 45° incident angle and equipped with a 45° germanium crystal. All spectra were 
normalized to the 1602 cm
-1
 peak corresponding to the C=C bond stretch of the aromatic 
ring located in both hard segments.  
5.2.5 Uniaxial Tensile Properties Dogbone specimens cut to ASTM D1708 
standard (n=5) were used to investigate the uniaxial tensile properties before and after in 
vitro degradation. Following cleaning and drying, specimens were strained at a rate of 10 
mm/min to failure using an Instron 3345 equipped with air-pneumatic tensile grips 
(Norwood, MA). Tensile stress values were calculated and plotted versus percent 
elongation. Initial (2%) secant modulus, tensile strength, and ultimate elongation were 
then calculated from the resulting curves. Percent recovery was measured after 
specimens were strained to failure. Briefly, permanent deformation, ΔL, of each 
fractured specimen was measured using the following equation:  
        , 
where Lf is the gauge length of the fractured specimen and L0 is the original gauge 
length. Percent recovery was then calculated using the following equation: 
                 (  
  
         
)         
5.2.6 Calorimetric Analysis Differential scanning calorimetry (DSC) was used 
to characterize thermal transitions in the polyurethanes (melting temperature (Tm) and 
glass transition temperature (Tg)) as well as changes in polymer crystallinity. 
Polyurethane specimens of approximately 5 mg in hermetic pans were first cooled to -
80°C and then heated to 80°C at a heating rate of 5°C/min using a TA Instruments 
Q2000 DSC (New Castle, DE). Changes in heat flow during the first scan were recorded 
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and plotted as a function of time. Transition temperatures were marked on the resulting 
DSC thermograms and enthalpy changes (ΔH) were calculated from the area of the 
melting peak. The percent crystallinity (% χc) was calculated from the equation: 
 
where ΔH  is 139.5 J/g for 100% crystalline PCL.612 
5.2.7 Molecular Weight Analysis Changes in molecular weight and molecular 
weight distribution were monitored using gel permeation chromatography (GPC). 
Briefly, specimens were dissolved in N,N’-dimethylformamide (DMF) with 0.1 M 
lithium bromide (LiBr) (Sigma Aldrich, Milwaukee, WI) at concentrations of 
approximately 5 mg/mL. GPC solutions were subject to vigorous stirring at 80°C for 24 
hours to ensure elimination of hydrogen bonding. Specimens were put through a 
GPCMax (Viscotek, Malvern, PA) equipped with two Phenomenex columns with pores 
measuring 10
3
 and 10
5
 Å in diameter. DMF with 0.05 M LiBr at a flow rate of 1.0 
mL/min at 60°C was used as an eluent and refractive index response was used as 
detection. OmniSEC software was calibrated using a set of narrow conventional 
calibration standards composed of polystyrene at known molecular weights of 
approximately 10, 50, 100, 300, 500, 800, and 1000 kDa (Agilent Technologies, Santa 
Clara, CA). Weight average molecular weight (Mw) and polydispersity index (PDI) were 
calculated and reported as average ± standard deviation. 
5.2.8 Surface Damage Scanning electron microscopy (SEM) was used to 
analyze the surface topography of PEsU and PEUU before and after 4 weeks 
degradation. An Au/Pd layer of approximately 200-300 Å was deposited on all 
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specimens prior to imaging to increase conductivity.  A JEOL 7500F field emission-
SEM (FE-SEM) was used to image the specimens with a 2 kV acceleration voltage and 
8mm working distance. Images were taken at magnitudes of 250X and 2000X to 
highlight both low and high magnification of surface topography features. 
5.2.9 Cell Viability Viability analysis of 3T3 fibroblasts on solvent casted 
PEsU and PEUU films was conducted using the Live/Dead
®
 Assay (Molecular Probes) 
to determine material cytocompatibility in comparison to tissue culture polystyrene 
(TCPS). NIH/3T3 Swiss mouse fibroblasts were purchased (ATCC-CCL92) and 
cultured with Dulbecco’s Modified Eagle Medium (DMEM-high glucose, GlutaMAX) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), and 1% penicillin-
streptomycin solution (Gibco). Prior to cell seeding, films were subjected to UV 
irradiation (1 hr per side), an ethanol wetting ladder to increase hydrophilicity, and 
overnight media incubation (37°C, 5% CO2) supplemented with 40% v/v FBS in DMEM 
at 37°C. Following incubation, media was removed, specimens dried in biosafety cabinet 
for 30 minutes, washed with phosphate buffered saline (PBS), and pre-conditioned with 
growth media for 15 minutes. Cells were seeded at 5,000 cells/cm
2
 and live/dead 
staining was performed at 24 and 72 hours. Percent cell viability was calculated from 
manual cell counts of images obtained through rastor patterning of 3 specimens (n = 15) 
with a fluorescence microscope (Nikon Eclipse TE2000-S). 
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5.3 Results and Discussion 
5.3.1 Initial Characterization Structural features of the PEsU were first 
examined with infrared spectroscopy. A characteristic ATR-FTIR spectrum of the PEsU 
film is shown in Figure 5.1 and was selected for analysis over transmission spectrum to 
enable assessment of phase morphology. ATR-FTIR peak assignments for the untreated 
PEsU are detailed in Table 5.1. Analysis of structural and morphological aspects of the 
PEsU revolves around analysis of the carbonyl region of the spectrum from 1800 – 1600 
cm
-1
. There are numerous carbonyls in the PEsU structure including soft segment alkyl 
esters, hard segment aryl esters, and hard segment urethanes. A complex ester/urethane 
carbonyl band envelope results from conformational differences between amorphous and 
ordered phases as well as free and hydrogen bonded carbonyls. Literature reports 
indicate that carbonyl stretching frequencies are typically lowered in ordered phases 
including crystalline solids and hydrogen bonding. A strong carbonyl absorbance at 
1725 cm
-1
 was attributed primarily to the crystalline polycaprolactone soft segment. The 
peak shoulder at 1695 cm
-1
 was assigned to the hydrogen-bonded urethane carbonyl 
based on standard literature assignments;
544
 and the peak shoulder at 1762 cm
-1
 was 
assigned to the aryl ester stretch of the hard segment.
613
 The carbonyl band envelope also 
contained the absorbance band of the free urethane carbonyl at 1730 cm
-1
 and 
amorphous alkyl ester at 1738 cm
-1
; however, full deconvolution of these peaks was not 
possible. The 1602 cm
-1
 peak in the PEsU spectrum was assigned to the C=C stretch of 
the aromatic ring within the hard segment based on previous assignations of 
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polyurethanes synthesized with MDI.
544
 Similarly, peaks at 1514 cm
-1
 and 1416 cm
-1
 
were assigned to C-C stretch in the aromatic ring within the hard segment.
544
  
In addition to confirmation of the aromatic nature of the PEsU, assessment of 
phase morphology using spectral features was conducted. Phase-separated hard domains 
in polyurethanes are stabilized by hydrogen bonds between hard segments. Therefore, 
hydrogen bonding of urethanes observed in the infrared spectrum can be used as a means 
to assess phase morphology.
215
 The N-H band at 3325 cm
-1
 observed in the spectrum of 
the PEsU indicates hydrogen bonding of the urethane hard segment.
544
 Multiple 
hydrogen bonding interactions are possible between the urethane N—H groups and the 
various carbonyls of both the hard and soft segments. However, the presence of the 
hydrogen-bonded carbonyl of the urethane at 1695 cm
-1
 indicates that at least a portion 
of the hydrogen bonding can be attributed to hard domain formation.  
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Figure 5.1 ATR-FTIR spectra of untreated PEsU film  
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Table 5.1. ATR-FTIR peak assignments of untreated PEsU 
Wavenumber (cm
-1
) PEsU Peak Assignment Reference 
3325 H-bonded N-H stretch, urethane Dillon et al. 
544
 
2947 asymmetrical CH2 stretch Dillon et al. 
544
 
2870 symmetrical CH2 stretch Dillon et al. 
544
 
1762 C=O stretch, aryl ester Jaffe et al. 
613
 
1738(sh) free amorphous C=O, ester Skarja et al. 
215
 
1730(sh) free C=O stretch, urethane Dillon et al. 
544
 
1725 crystalline C=O stretch, ester  Skarja et al. 
215
 
1714(sh) H-bonded amorphous C=O stretch, ester  -- 
1695(sh) H-bonded C=O stretch, urethane Dillon et al. 
544
 
1602 C-C stretch, benzene ring Dillon et al. 
544
 
1541 C-N stretch + N-H bend, urethane Dillon et al. 
544
 
1514 C-C stretch, benzene ring Dillon et al. 
544
 
1459 aliphatic CH2 bend Dillon et al. 
544
 
1416 C-C stretch, benzene ring Dillon et al. 
544
 
1396 aliphatic CH2 wag David et al. 
614
 
1366 aliphatic CH2 wag David et al. 
614
 
1296 crystalline C-O and C-C stretch, ester Elzein et al. 
615
 
1259(sh) CH2 wag Khosroshahi et al. 
616
 
1240 asymmetric C-O-C stretch, ester Elzein et al. 
615
 
1211 OC-O stretch, aryl ester -- 
1188 OC-O stretch, ester Elzein et al. 
615
 
1163 symmetric C-O-C stretch, ester Elzein et al. 
615
 
1107 symmetrical C-O-C stretch Dillon et al. 
544
 
1088(sh) symmetrical C-O-C stretch, urethane Dillon et al. 
544
 
1066 asymmetrical C-O-C stretch, urethane Dillon et al. 
544
 
1045 symmetrical C-O-C stretch Dillon et al. 
544
 
962 C-H wag, benzene ring Dillon et al. 
544
 
829 C-H out of plane bending, benzene ring Dillon et al. 
544
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Thermal transitions in the PEsU were examined with differential scanning 
calorimetry, Figure 5.2. Scans of untreated PEsU indicate a melting transition (Tm) at 
approximately 45°C and a glass transition temperature (Tg) at -35°C.
617
 These transitions 
are primarily due to the polycaprolactone soft segment and are shifted from commonly 
reported PCL values of Tg = -60ºC and Tm = 60ºC. These transition temperatures were 
consistent with the reported values of PCL-based polyurethanes.
215,511
 The increase in Tg 
was attributed to the constraining effect of hard domains and a degree of phase mixing 
with the more rigid hard segments. The relative degree of phase mixing can be estimated 
by the increase in Tg from the pure soft segment. Skarja et al. reported a range of phase 
separation in PCL-based polyurethanes from nearly complete phase separation with a Tg 
only 8ºC above pure PCL (-52°C) and fully phase mixed with Tg values approaching 
0ºC.
215
 These reference values indicate that the PEsU in this study had a moderate level 
of phase separation which is also supported by the infrared spectral evidence of 
hydrogen bonding of hard segments described above. The depressed melting temperature 
as compared to PCL was attributed to reduced order of the crystalline domains due to 
phase mixing with the hard segment. The ability of PCL segments to crystallize in 
segmented polyurethanes is also impaired by the connection with hard segments and the 
corresponding decrease in the conformational mobility of the PCL soft segment chains.  
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Figure 5.2. DSC thermogram (first scan) of untreated PEsU 
 
The stress–strain behavior of PEsU is typical of a semicrystalline polymer above 
its Tg, in agreement with the DSC findings, Figure 5.3. The PEsU displayed a yield 
point followed by necking and drawing similar to semicrystalline PCL polyurethanes 
reported in the literature.
215,511,609,618,619
 The PEsU were characterized by 2% secant 
modulus of 58 ± 5 MPa, tensile strength of 30 ± 3 MPa, and ultimate elongation of 677 ± 
7%. The high modulus and tensile strength of PEsU was attributed to the semicrystalline 
soft segment and high cohesion hard domains. Soft segment crystalline domains are 
proposed to act as physical crosslinks similar to the traditional description of hard 
domains in segmental polyurethanes. Several studies have reported enhanced tensile 
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properties as a function of both increased phase separation and polyester soft segment 
crystallinity. PEsU outperformed BDI, HMDI and LDI-based SPUs with similar polyol 
and chain extender chemistries likely due to the contribution of the aromatic isocyanate, 
Table 5.2.
618,619
 These enhanced properties is believed to result from the increased hard 
domain cohesion observed in polyurethanes with aromatic hard segments.
620
 A 
significant amount of permanent set was also observed with percent recovery calculated 
to be 65 ± 4%. Given the relative high recovery of polyether-based polyurethanes, the 
permanent set was attributed to the deformation of soft segment crystalline domains.  
 
 
Figure 5.3. Stress-strain plot of untreated PEsU specimen uniaxially loaded at a rate of 
10 mm/min to failure  
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Table 5.2. Comparison of effects of hard and soft segment content and chemistry on material properties poly(ester 
urethanes) and poly(ester urethane ureas) 
Isocyanate Polyol 
Initial 
Modulus 
Tensile 
Strength 
Tg 
(°C) 
Tm 
(°C) 
ΔHm 
(J/g) 
Percent 
Crystallinity 
Reference 
G-E-G-G DI PCL 58 MPa 30 MPa -35 45 20.4 15%
ǂ
 -- 
BDI PCL2000 23 MPa 23 MPa -54 24, 69 9, 11 6, 8%
ǂ
 Spaans et al. 
619
 
HDI PCL1250 38 MPa -- -53 25, 60 16, 2 11, 1%
ǂ
 Chiono et al. 
621
 
HDI PCL1250 20 MPa 28 MPa -33 42 47* 35% Skarja et al. 
511
, 
215
 
HDI PCL2000 20 MPa 28 MPa -52 45 -- -- Skarja et al. 
511
 
HMDI PCL1250 3 MPa 19 MPa -39 7 -- -- Sarkar et al. 
609
 
(
ǂ
value calculated using method from Zhang et al.
612
) *100% crystallization determined by melting point depression of 
PCL with ethyl benzoate (3 .  cal/g), ΔHm value back-calculated 
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Finally, assessment of 3T3 cell viability on PEsU films after 24 and 72 hours was 
performed to assess the cytocompatibility of the material as compared to a commercial 
polyurethane control (PEUU) currently used in biomedical devices, Figure 5.4. PEsU 
cell viability results were comparable to both PEUU and the TCPS control after 24 
hours. Similar levels of cell viability after 24 hours was previously reported for aliphatic 
polyurethanes of similar soft segment and chain extender composition.
506
 After 72 hours 
PEsU films exhibited a small decrease in viability (86 ± 6 %) with PEUU remaining 
statistically similar to the TCPS control (97 ± 3 %). 
 
 
Figure 5.4. Comparison of viable 3T3 mouse fibroblasts (Live/Dead) on tissue culture 
polystyrene (TCPS), PEsU, and PEUU after 24 and 72 hours. 
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5.3.2 In Vitro Biodegradation A commercially available poly(ether urethane 
urea), BioSpan
®
 80A, was selected as a control for in vitro degradation studies due to its 
established hydrolytic stability. Infrared spectral analysis of surface and bulk chemistry 
was performed on untreated and treated specimens. Characteristic transmission-FTIR 
spectra are shown in Figure 5.5 and indicate minimal changes in the bulk chemistry of 
the polyurethanes after 4 weeks of accelerated hydrolytic treatment (0.1 M NaOH). In 
contrast, ATR-FTIR spectra of the PEsU specimens indicated soft and hard segment loss 
after treatment in PBS and accelerated 0.1M NaOH solutions for 4 weeks, Figure 5.6. 
Closer examination of the carbonyl region of these spectra, Figure 5.7, revealed 
preferential loss of free urethane at 1730 cm
-1
 and reduction of peak heights 
corresponding to the aryl ester at 1762 cm
-1
, the amorphous alkyl ester at 1738 cm
-1
, and 
hydrogen bonded urethane at 1695 cm
-1
 after incubation in PBS. Complete loss of the 
aryl ester peaks at 1762 cm
-1
 and 1211 cm
-1
 was observed after accelerated hydrolytic 
treatment. In contrast to many PCL-based SPUs, these results indicate that the PEsU 
displayed significant hard segment loss while retaining the crystalline PCL soft segment, 
as indicated by retention of strong absorbances at 1725 cm
-1
 and 1296 cm
-1
. 
622
 This 
preferential loss of the hard segment prior to the PCL soft segment was attributed to the 
more hydrolytically labile isocyanate in the PEsU. As expected, no evidence of surface 
chemistry changes was observed in the spectra of the PEUU specimens after treatment. 
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Figure 5.5 Transmission-FTIR spectra of (A) PEsU in PBS, (B) PEsU in 0.1 M NaOH, 
(C) PEUU in PBS, and (D) PEUU in 0.1 M NaOH before and after in vitro hydrolytic 
degradation. 
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Figure 5.6 ATR-FTIR spectra of (A) PEsU in PBS, (B) PEsU in 0.1 M NaOH, 
(C) PEUU in PBS, and (D) PEUU in 0.1 M NaOH before and after in vitro hydrolytic 
degradation 
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Figure 5.7. Carbonyl stretch region of ATR-FTIR spectra from PEsU specimens in PBS and 0.1 M NaOH before and after 
in vitro hydrolytic degradation. 
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GPC results indicate substantial loss of PEsU molecular weight (MW) after 4 weeks in 
both PBS and 0.1M NaOH solutions indicating substantial chain scission, Figure 5.8. A 
reduction of approximately 25% of its initial molecular weight was observed after 4 
weeks in PBS, similar to results seen in aliphatic PCL-based polyurethanes.
208
 Similar to 
the infrared findings, the 0.1 M NaOH solution accelerated molecular weight loss of the 
PEsU to more than double the percent molecular weight loss observed in PBS, ~54%. 
This result was somewhat surprising given the lack of changes observed in the 
transmission spectra of treated polyurethane specimens that indicates retention of bulk 
chemistry. In contrast, the molecular weight of PEUU specimens after 4 weeks was 
statistically similar to untreated control values indicating resistance to hydrolytic chain 
scission. Gravimetric analysis indicated that PEsU specimens experienced minor mass 
loss in PBS, similar to literature reports of the PCL homopolymer.
623
 Substantial mass 
loss (31.3 ± 1.4%) was observed in the accelerated 0.1 M NaOH solution after four 
weeks, Table 5.3. The PEUU specimens showed no significant mass loss in either 
solution, as expected given the retention of molecular weight.  
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Figure 5.8 GPC Chromatograms of (A) PEsU and (B) PEUU specimens before and after 
in vitro hydrolytic degradation 
 
 
 
 
 
 127 
 
Table 5.3. Percent mass loss after in vitro biodegradation. 
 PEsU PEUU 
 PBS 0.1 M NaOH PBS 0.1 M NaOH 
1 week 3.5 ± 0.1 9.1 ± 0.6 0.8 ± 0.1 0.8 ± 0.1 
2 weeks 4.6 ± 0.3 20.7 ± 0.5 0.6 ± 0.2 1.1 ± 1.8 
3 weeks 2.8 ± 0.3 25.1 ± 0.5 0.9 ± 0.2 0.8 ± 0.1 
4 weeks 5.4 ± 5.3 31.3 ± 1.4 1.0 ± 0.2 0.6 ± 0.7 
(average ± standard deviation; n=4) 
 
 
Scanning electron micrographs revealed increased surface roughness of PEsU 
specimens incubated in PBS; whereas, specimens incubated in NaOH displayed 
substantial surface cracking after 4 weeks, Figure 5.9. The change in surface roughness 
is likely an indicator of minor erosion limited mainly to the surface of the material. 
Specimens immersed in 0.1 M NaOH display more substantial degradation with deep 
cracking similar to previously reported degradation of PCL-based polyurethanes.
622
 This 
type of “mud-cracking” is representative of a degradation profile where the polymer 
undergoes chain scission (molecular weight loss) followed by extraction of low 
molecular weight chains (mass loss). During drying, shrinkage of the degraded surface is 
constrained by the bulk of the polymer specimen leading to internal stresses that cause 
non-directional cracking. Finally, no changes were observed in PEUU topography after 4 
weeks of accelerated degradation.  
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Figure 5.9. Scanning electron micrographs of (A) PEsU in PBS, 
(B) PEsU in 0.1 M NaOH, (C) PEUU in PBS, and (D) PEUU in 0.1 M NaOH before and 
after in vitro hydrolytic degradation 
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Uniaxial tensile testing of degraded PEsU specimens showed significant differences in 
the mechanical responses when compared to the untreated material, Figure 5.10. Initial 
modulus was the most substantial change with a drop from 57 ± 5 MPa to 11 ± 1 and 
17 ± 5 MPa for PBS and NaOH specimens, respectively. Tensile strength was also 
reduced after degradation from 29 ± 3 MPa for untreated specimens to 17 ± 2 MPa for 
PBS specimens and 15 ± 4 MPa for NaOH specimens. DSC thermographic analysis of 
both treatment groups revealed significant changes in thermal transitions and 
crystallinity, Figure 5.11. First, a decrease in soft segment Tg was observed in NaOH 
specimens from -35ºC to -45°C; whereas, minimal changes in Tg were observed in 
specimens incubated in PBS (-35ºC versus -37ºC). More notably, changes in the soft 
segment crystallinity were observed in both treatment groups with more significant 
changes again observed after base accelerated hydrolysis treatment. Untreated specimens 
had a typical melting transition of  5ºC and a ΔH of   .  J/g that corresponded to 
approximately 15% crystallinity. Treatment in PBS for 4 weeks resulted in a small 
increase in the melting transition to 49ºC, a significant decrease in percent crystallinity 
to 7% (ΔH    .9 J/g), and a broad cold crystallization peak at 3ºC (ΔH    .9 J/g). The 
NaOH specimens exhibited two melting transitions at Tm,1     ºC (ΔH1=10.1 J/g) and 
Tm,2   5 ºC (ΔH2 = 9.9 J/g) and a more pronounced cold crystallization peak at -1ºC (ΔH 
= 9.5 J/g). The loss of crystallinity was attributed to soft segment chain scission that was 
confirmed in infrared and GPC analyses. It is also likely that this chain scission provided 
greater mobility to the soft segment chains allowing for enhanced order of the remaining 
crystallites and a corollary increase in melting temperature. These results correlate well 
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with the infrared findings that indicate that the remaining soft segment was highly 
crystalline. The cold crystallization was attributed to quenching the polymer from the 
treatment solution at 37ºC, which is above the melting transition, to -80 ºC in the first 
DSC scan. The liberated soft segment chains were then able to reorganize during the 
heating scan to form crystallites of reduced order and lower melting temperature. 
Overall, the reduced modulus of the PEsU after treatment was attributed to the loss of 
crystallinity of the PCL soft segment due to hydrolytic chain scission. 
5.4 Conclusions  
In summary, we have characterized the physical properties of a novel resorbable 
PEsU synthesized with biodegradable aromatic isocyanates before and after accelerated 
hydrolytic degradation. Infrared spectral analysis confirmed the aromatic and phase-
separated nature of the PEsU. Uniaxial tensile testing displayed stress-strain behavior 
typical of a semicrystalline polymer above its Tg, in agreement with calorimetric 
findings. PEsU outperformed aliphatic PCL-based polyurethanes likely due to the 
enhanced cohesion of the aromatic hard domains. Accelerated degradation of the PEsU 
using 0.1 M sodium hydroxide resulted in hydrolysis of the polyester soft segment on the 
surface, reduced molecular weight, surface cracking, and a 30% mass loss after four 
weeks. Calorimetric studies indicated a disruption of the soft segment crystallinity after 
incubation which corresponded with a drop in initial modulus of the PEsU. Finally, 
cytocompatibility testing with 3T3 mouse fibroblasts exhibited good cell viability on 
PEsU films after 24 hours. Overall, this new resorbable polyurethane exhibits 
mechanical properties superior to current aliphatic designs along with a favorable 
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degradation profile making it an ideal candidate for inclusion in a future TEVG 
multilayer design. 
 
 
Figure 5.10. Stress-strain plots of PEsU in PBS and PEsU in 0.1 M NaOH before and 
after 4 weeks in vitro hydrolytic degradation uniaxially loaded at a rate of 10 mm/min to 
failure 
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Figure 11. DSC thermograms (first scan) of PEsU in PBS and PEsU in 0.1 M NaOH 
before and after in vitro biodegradation. 
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CHAPTER VI  
CONCLUSIONS 
 
6.1 Summary  
In this work, the material properties of various segmented polyurethanes were 
optimized for use as a reinforcing electrospun layer of a small-diameter multilayer 
vascular graft. Previous synthetic options lacked the appropriate thromboresistance and 
matching compliance needed for long term deployment success in small diameter (d < 6 
mm) applications. The proposed multilayer vascular graft design in this work 
incorporated an intimal PEG-Scl2-2 hydrogel layer expected to provide 
thromboresistance and in situ rapid endothelialization which would prevent acute graft 
occlusion.  An electrospun thermoplastic polyurethane reinforcing layer was then 
employed to provide the requisite biomechanical properties and biostability needed for 
ensured long term success in vivo. The feasibility of the multilayer vascular graft design 
was confirmed with successful multilayer graft integrity testing and acute in vivo success 
of early prototypes. The initial success then prompted further investigation into 
optimizing the material characteristics of the electrospun reinforcing layer. 
Compliance matching was a key functional requirement of the reinforcing 
vascular graft layer to ensure high long term patency rates by preventing intimal 
hyperplasia. Current synthetic options and early SPU vascular graft designs often 
provide burst pressure exceeding the current saphenous vein properties but lack 
sufficient compliance to ensure long term success. Investigation into the semi-IPN 
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approach detailed in this work provided improved biomechanical properties of the 
electrospun graft. Furthermore, the required heat treatment to synthesize the silicone 
network within the semi-IPN chemistries had a beneficial annealing effect on grafts 
composed of only the PCU component. To the best of our knowledge, no synthetic small 
diameter graft with compliance and burst pressure values that simultaneously exceeded 
saphenous vein biomechanical properties had been previously reported. 
In addition to compliance matching and burst pressure maintenance, the long 
term biostability of the reinforcing layer needed to be optimized. The in vitro oxidative 
stability of several commercially available PCUs was investigated using both the 
established accelerated metal ion oxidation protocol and the ISO 10993 physiological 
rate protocol. The demonstrated biostability of all of the PCU samples showed long term 
resistance to environmental stress cracking ensuring high probability of implantation 
success. Furthermore, the accelerated in vitro oxidation method was the only treatment 
which produced data comparable to previously reported in vivo studies making it the 
favorable protocol over the ISO 10993 method. 
In addition to biostable designs, we have characterized a novel biodegradable 
aromatic PEsU for a new tissue engineered vascular graft design which allows for 
restoration of graft vasoactivity. Along with improved initial mechanical properties over 
previous aliphatic biodegradable SPU designs, this PEsU was expected to degrade into 
safe degradation byproducts. Favorable initial cytocompatibility testing and resultant 
degradation made it a promising choice for future tissue engineering vascular graft 
designs and other biomedical devices. 
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6.2 Significance of Work 
 Segmented polyurethanes already remain a prominent material selection choice 
for biomedical device designs due to excellent mechanical properties, fatigue strength, as 
well as their established bio and hemocompatibility. The high tunability of these 
materials stemming from their known microphase morphology allows for favorable 
tailoring of the reinforcing layer of our multilayered vascular graft.  The added benefit of 
electrospinning gave further control over graft architecture which provided compliance 
and burst pressure values comparable to reported autologous saphenous graft properties. 
These resultant properties then allowed for strong initial multilayer graft integrity testing 
results and promising acute in vivo porcine model testing studies. The initial findings 
from these feasibility studies then prompted investigation into further optimizing the 
reinforcing layer of the multilayer vascular graft design. 
 In Chapter 3, we addressed the problem associated with the inverse relationship 
between compliance and burst pressure of previous synthetic options including several 
polyurethane-based designs. To the best of our knowledge, no prior art had presented a 
synthetic option capable of matching compliance while simultaneously providing 
sufficient burst pressure. Using our proposed semi-IPN approach, we were able to 
simultaneously improve the compliance and burst pressure of our electrospun grafts over 
reported saphenous vein properties. Additional investigation into the effect of the 
heating cycle for covalent network formation exposed an added beneficial annealing 
effect on the polyurethane component resulting in improved pure PCU biomechanical 
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properties. The improved compliance and burst pressures of these electrospun samples 
shows promise in ensuring long term patency of our multilayer grafts. 
 In Chapter 4, the biostability of the materials potentially used for the reinforcing 
layer of our vascular graft was explored to ensure long term performance of the electron 
meshes.  The effects of modulating polycarbonate soft segment chemistry, soft segment 
content, and silicone modification were all limited to surface characterizations like ATR-
FTIR spectroscopy and SEM, the bulk of all 6 materials were found to be unaffected. 
While ensuring biostability of these grafts is always important, the predictive capabilities 
of the in vitro test methods employed in this work were also evaluated. Using an 
iodometric titration method to quantify changes in H2O2 content, the accelerated method 
was the only in vitro treatment found to produce reactive oxygen intermediates. The lack 
of changes in H2O2 levels within the 3% H2O2 system were then found to be the root 
cause of no degradation evidence in any of the materials after 12 months despite 
previous in vivo data within the same time frame. Base on this work, the metal ion 
accelerated method should be considered as the superior treatment system for predicting 
oxidative stability of SPUs. 
 In Chapter 5, we explored the option of a biodegradable reinforcing electrospun 
layer as part of a tissue engineered vascular graft design intended to restore vasoactivity 
instead of mimicking autologous graft properties. Biodegradable SPU formulations have 
typically been limited to aliphatic designs due to concerns over carcinogenic aromatic 
degradation byproducts. The aromatic PEsU intended for use in our design contained a 
biodegradable hard segment expected to degrade into safe byproducts while providing 
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superior mechanical properties. Early cytocompatibility testing along with a strong 
favorable degradation profile and novel electrospun patterning techniques make this 
PEsU very promising for future biodegradable TEVG designs along with other 
biomedical devices. 
 Overall, the demonstrated tunability of segmented polyurethanes makes them 
strong candidates for the electrospun reinforcing layer of our multilayer graft design. 
The improved biomechanics from the heat treatment and semi-IPN approach provide 
strong confidence in long term patency of our grafts. In addition, the demonstrated 
biostability ensures long term functional capabilities of our grafts without failure due to 
ESC. Furthermore, the structure-property relationship knowledge gained from these 
studies allows for future SPU reinforcing layer component designs with superior 
biomechanical properties, biostability or even biodegradability. 
 
6.3 Challenges and Future Directions 
Although this work shows strong promise in the areas of matching graft 
properties and biostable/biodegradable graft designs, there are still several questions that 
need to be addressed moving forward. Given the demonstrated effect of heat treatment 
on electrospun grafts, prolonged exposure to temperatures higher than typical room 
temperatures needs to be explored. In this work, longer heat treatments of several grafts 
showed further improved microphase separation but more severe effects on graft 
architecture ultimately resulting in reduced compliance. Our grafts will be subject to a 
mild heat treatment throughout the entire implantation period which could potentially 
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affect material properties and/or graft architecture over time.  Therefore long term 
exposures to heat under static and pulsatile flows should be investigated in future 
studies. 
In addition to heat treatment effects, only initial mechanical properties were 
explored in this study. Effects of prolonged cyclic loading over an approximated 
implantation period should be explored to monitor potential changes in graft properties 
due to fatigue. Given fatigue strength is expected to stay high with a polyurethane-based 
reinforcing layer, this effect could be presumed to be minimal however, electrospinning 
has already been demonstrated to alter SPU microphase morphology.  Therefore, fatigue 
strength of these electrospun grafts can also be changed. 
The PCUs investigated in this work all demonstrated strong resistance to 
oxidation and low potential for failure due to ESC. The PEsU investigation was also 
shown to have a favorable degradation profile for tissue engineering graft designs. 
However all these in vitro tests were performed on melt-extruded or solvent cast films, 
not electrospun grafts. A highly porous graft such as the reinforcing fibrous mesh in our 
multilayer design, provides a much higher surface to volume ratio than neat films which 
could accelerate degradation rates further. Effects of architecture would need to be 
explored along with changes in material chemistry of these grafts. 
Finally, all in vitro testing was also performed on grafts in only static conditions. 
Given that our multilayer grafts will be subject to a consistent pulsatile loading cycle, the 
reinforcing layer of our design should be tested in a bioreactor that provides both the 
degradation media as well as presumed cyclic loading. The designed bioreactor setup is 
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expected to better provide a more physiological environment than our current static 
degradation setups. 
While this work may appear to be extensive and complex, the potential 
knowledge gained from these future studies could allow for more advanced insight into 
graft structure property relationships. Thus future multilayer vascular graft design are 
expected include further improved biomechanical properties, potentially enhanced 
biostability, and even greater control over biodegradation for vasoactivity restoration. 
Overall, the results from the proposed work are expected to provide a clearer path 
towards a greater chance of long term implantation success from the next generation of 
multilayer vascular grafts. 
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APPENDIX A  
MICROPATTERNING OF ELECTROSPUN POLYURETHANE FIBERS THROUGH 
CONTROL OF SURFACE TOPOGRAPHY 
 
A.1 Introduction 
Electrospinning has gained increasing popularity in tissue engineering as a facile 
and tunable process to generate high porosity scaffolds. Current research has expanded 
the versatility of electrospinning through controlled fiber alignment and assembly. Fiber 
alignment is of particular interest in tissue engineering because topographical features 
have been shown to strongly influence cellular alignment on a substrate. Thus, control of 
electrospun fiber alignment can be used to generate desired cellular distributions and 
orientations within the tissue engineered construct. Fiber alignment and patterning can 
also be used to enhance mechanical properties and mimic the native orientation and 
anisotropic properties of native tissues. Common methods to control the fiber alignment 
and patterning include setups that utilize a spooling collector rather than a stationary 
target
182,624-628
 and setups that modulate the electric field.
629-632
 Spooling setups induce 
specific fiber orientations by physical manipulation of the resulting fibers using a 
moving collector stage,
633,634
 revolving disk,
635
 or rotating mandrel.
636
 Modulation of the 
electric field with different setups has been used to create a range of fiber geometries 
*Reprinted with permission from “Micropatterning of electrospun polyurethane fibers 
through control of surface topography,” by D. K. Dempsey, C. J. Schwartz, R. S. Ward, 
A. Iyer, J. Parakka, and E. Cosgriff-Hernandez, Macrmolecular Materials and 
Engineering 2010, 295, 990-994. Copyright (2010) Wiley. 
 237 
 
including leaf patterns,
637
 aligned fibers stacks,
638
 and fiber arrays with grounded rings 
to wind into yarn.
639
 Recently, modification of the collector’s surface topography has 
shown great promise in controlling fiber deposition. Selective deposition was observed 
on electroconductive templates (woven wire meshes) and resulted in improved 
mechanical properties of the resultant fiber mats.
640
 Alternative collectors with different 
surface topographical features have also affected cell adhesion patterns on electrospun 
fiber mats.
641
 Pan et al. showed that fibers align themselves creating grid patterns 
between adjacent conducting pins inserted within an insulating surface.
642
 Zhang et al. 
demonstrated that electrospun fibers are attracted to raised topographical features of 
conducting substrates with raised patterns.
643
 In contrast, Ding et al. utilized field-
enhanced electrospinning on an elastomeric substrate with gold-coated pyramidal 
protrusions to increase the population of fibers at raised points.
644
 Similar to the works 
by Pan and Zhang, the effect was attributed to a redistribution of the electric field in 
close proximity to the collector as a result of the change in surface topography of the 
substrate.
642-645
 Although these studies have laid the foundation for the mechanistic 
understanding of the selective fiber deposition process, great strides are still needed  
enable the practical application of patterning techniques in the fabrication of improved 
tissue engineering constructs.  
In this communication we present a simple method of manipulating the 
morphology and arrangement of electrospun polyurethane fibers by controlling the 
surface topography of an insulating collector substrate. Two polyurethanes, poly(ester 
urethane) (PEsU) and poly(ether urethane urea) (PEUU), were electrospun onto 
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patterned silicone substrates generated with standard soft lithography techniques. The 
effect of surface topography on selective fiber deposition and bundling was investigated. 
Particular attention was given to material-specific effects on fiber deposition patterns 
which were previously unexplored in the literature. Our results showed patterned PEsU 
fibers and randomized PEUU fibers indicating that this effect is material specific. 
Specifically, alignment of the polar carbonyls of the polyester soft segment in the 
electric field was hypothesized to result in fiber attraction and increased patterning 
throughout the deposition period. Overall, the combination of low cost, ease of use, 
tunability, and generation of relatively large fiber mats available with this technique 
greatly expands the utility of patterned electrospun scaffolds in tissue engineering and 
other biomedical applications. 
 
A.2 Materials and Methods 
A.2.1 Materials BioSpan
®
, a commercially available poly(ether urethane urea) 
(PEUU), and an experimental bioresorbable poly(ester urethane) (PEsU) were 
synthesized by DSM-Polymer Technology Group (Berkeley, CA, USA). Transmission 
FTIR spectra of neat polyurethanes were recorded using a Bruker TENSOR 27 Fourier 
transform infrared spectrometer by solution casting directly onto KBr pellets to elucidate 
key structural features, Figure A.1. The dominant peak in the PEsU spectra is located at 
1730 cm
-1
 and corresponds to the stretching of the free carbonyl group (C=O) of the 
ester linkage in the soft segment. For PEUU, the major peak is found at 1110cm
-1
 and 
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corresponds to the stretching of the ether group (C-O-C) in the soft segment of the 
polymer.  
 
Figure A.1. FTIR spectra of PEsU and PEUU. 
 
A.2.2 Soft Lithography Standard photolithography processes were used to 
prepare epoxy-based master molds (SU-8, MicroChem) with raised square patterns 
approximately 12µm high and lengths of 50, 100, 200, and 500 µm. These molds were 
then used to create negative PDMS replica of these patterns via soft lithography to 
generate PDMS collector substrates with raised grid patterns. Briefly, a PDMS elastomer 
kit (Sylgard 184, Dow Corning) was first mixed at a standard 10:1 base to curing agent 
ratio. The master mold was treated with a chemical release agent, (Tridecafluoro-1,1,2,2-
Tetrahydrooctyl)-1-Trichlorosilane and the mixed elastomer spin-coated (Laurell 
Technologies Corporation) onto the mold at 500 rpm for 25 seconds to ensure that a 
uniform, thin layer of PDMS (~300 µm) was applied. The PDMS/mold assembly was 
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then cured in an oven at 85°C for 20 minutes. A 200 Å-thick gold/palladium layer was 
deposited on the PDMS collector sheets by sputter coating to prevent PDMS swelling 
from contact with solvent during electrospinning. The layer of gold/palladium was not 
expected to affect the conductivity of the collector as there was no contact of the sputter 
coated material with the plate behind the PDMS substrates. Indeed, fiber patterning and 
bundling was observed without substrate coating; however, solvent swelling of the 
PDMS substrate prevented removal of the fiber mesh and full characterization (data not 
shown). 
A.2.3 Electrospinning PEUU and PEsU solutions (15 wt%) were prepared in 
N,N‘ dimethylacetamide (DMAC) (Sigma Aldrich) and dispensed from    mL glass 
syringes at a rate of 0.2 mL/hr, as controlled by a syringe pump (KDS100, KD 
Scientific). A high voltage source (Gamma High Voltage) was used to apply 8.5kV to 
the tip of a blunted 23g1 needle attached to the glass syringe. Electrospun fibers were 
collected on both patterned and flat PDMS sheets attached to the front face of a copper 
plate which was grounded and positioned 20 cm from the tip of the needle. Electrospun 
fibers were collected for 2 hours and fiber mats removed from the collector sheets prior 
to characterization. 
A.2.4 Characterization Surface topography images of the patterned, silicone 
collector sheets were obtained using an optical profilometer (Zygo Corporation) 
equipped with a 10x objective. Five scans of 40 µm lengths were average to minimize 
noise. High resolution images of electrospun fiber mats were captured using a field 
emission – scanning electron microscope (JSM-7500F, JEOL) operated at 2kV. 
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Quantification of grid dimensions and electrospun fiber diameters were determined 
using pixel to length ratios of dimensions measured in SEM and profilometer images. 
Briefly, 15 edge-to-edge measurements of each silicone and electrospun fiber grid were 
obtained on three specimens for a total of 45 measurements. For quantification of fiber 
diameter, measurements were made on the first fifteen fibers that intersected a line 
drawn across the middle of an image. Images from three specimens were used for a total 
of 45 measurements. Average dimensions and standard deviations were reported. 
 
A.3 Results and Discussion 
The selected surface topography designs were raised grid patterns 20 µm wide 
with approximate heights of 12 µm and spacing of 50, 100, 200, and 500 µm. The results 
from the optical profilometer indicated successful fabrication of the anticipated surface 
topography of the PDMS replica, Figure A.2 with minimal deviation from the intended 
dimensions, Table A.1. In order to isolate the effect of the patterned surface topography 
from other electrospinning variables, the polymer concentration (15 wt%), solution flow 
rate (0.2 mL/hr), output voltage (8.5 kV), distance to collector (20 cm), and spinning 
time (2 hours) were kept constant. PEsU and PEUU were both electrospun onto flat and 
patterned PDMS substrates and the resulting morphologies observed with scanning 
electron microscopy. Figure A.2 shows the successful patterning of PEsU fibers which 
reproduced the grid pattern of the PDMS collector substrate, Table A.1. Quantitative 
analysis of fiber diameter revealed a bimodal distribution with random fibers ranging 
from 1.4-1.9 microns in diameter and what appear to be fused fiber bundles that were an 
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order of magnitude larger than the random fibers (16-22 microns), Table A.1. The high 
magnification image of these fiber bundles, Figure A.3 appears to indicate that the 
overlay of fibers and subsequent fusion resulted in the observed bimodal distribution. 
Figure A.3C shows the comparison between PEUU and PEsU fibers electrospun onto 
flat PDMS substrates which served as a negative control for topographical effects on 
fiber deposition. As expected, neither the PEsU nor the PEUU fibers showed any 
patterning on the flat substrate though the PEsU fibers did still exhibit random fiber 
bundling. 
 
Table A.1. Dimensions of resultant PDMS collectors and electrospun PEsU fiber mats 
 
PDMS    
Grid Size 
Fiber Pattern 
Grid Size 
PEsU Bundled 
Fibers 
PEsU Random 
Fibers 
PEUU Random 
Fibers 
50 µm 
Grid 
54 ± 2 µm 45 ± 3 µm 20 ± 2 µm 1.4 ± 0.2 µm 0.8 ± 0.3 µm 
100 µm 
Grid 
103 ± 1 µm 85 ± 7 µm 22 ± 4 µm 1.9 ± 0.5 µm 0.8 ± 0.2 µm 
200 µm 
Grid 
202 ± 1 µm 193 ± 14 µm 17 ± 6 µm 1.4 ± 0.3 µm 0.9 ± 0.2 µm 
500 µm 
Grid 
500 ± 2 µm 400 ± 20 µm 22 ± 7 µm 1.5 ± 0.3 µm 0.9 ± 0.2 µm 
Flat 
PDMS 
-- -- 16 ± 4 µm 1.5 ± 0.4 µm 0.8 ± 0.2 µm 
(n = 45; average ± standard deviation) 
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Figure A.2. Optical profilometer scans of patterned PDMS collector substrates (left) and 
scanning electron micrographs of the resultant electrospun PEsU fibers (right) for 
(A) 50 µm, (B) 100 µm, (C) 200 µm, and (D) 500 µm 
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During the electrospinning process, the initial movement of the charged fibers is 
randomized.
646
 However, the motion after ejection is controlled by electrostatic forces 
exerted by the external field, collector, and any adjacent charged fibers.
629-632,640-643
 In 
the flat collector plate setup, there is no preferential direction in the plane of the collector 
resulting in a random fiber mesh. Whereas, a patterned collector substrate results in 
selective fiber deposition and arrangement due to an increase in Coulomb interactions 
with the raised topographical features of the collector.
645
 When this theory is applied to 
the patterned PDMS substrates used in the current study, two effects are in competition. 
The increased thickness of the insulator at the raised features results in increased charge 
dissipation; however, there is also a shorter distance between the raised features and the 
charged needle thus creating stronger electric fields. The effect of a shortened distance 
between charges is dominant and resulted in the observed fiber patterning.
188
 This was 
found to be true only at relatively thin insulating substrate thicknesses (~300 µm) 
achieved by spin-coating the PDMS onto the SU-8 mold. Thicker PDMS substrates were 
initially used (results not shown) and it was observed that very few fibers were attracted 
to the collector because of the weakened electric field. 
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Figure A.3. Scanning electron micrographs of PEsU (left) and PEUU fibers (right) 
electrospun on (A) patterned PDMS; (B) high magnification on patterned PDMS; 
(C) flat PDMS. 
 
The theory described above is consistent with the current literature of 
electrospinning on patterned conducting substrates; however, it does not address the 
material specificity of patterning observed in the current study. Typically in 
electrospinning, the solvent reduces the viscosity of the polymer to enable fiber drawing 
A 
B 
C 
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and provides sufficient conductivity for the polymer solution to be electrospun. Thus, 
solvents with higher dipole moments are subject to greater electrical forces which 
impacts the ‘electrospinnability’ of the polymer solution.187 The comparisons between 
the PEsU fibers and the PEUU fibers seen in Figure A.3 show a distinct difference in 
the effect of the patterned PDMS despite having the same conductive solvent, 
dimethylacetamide. Therefore, the difference in patterning was attributed to differences 
in contribution to the total dipole moment from the polymers themselves, specifically, 
the carbonyl of the ester linkages in the soft segment of the PEsU that are absent in the 
PEUU. It should be noted that urethanes also contain carbonyl groups; however, the two 
polyurethanes have similar and relatively low hard segment content which appears to 
have mitigated their effect on fiber deposition.  
Fused fiber bundles were observed in the micrographs of PEsU fibers electrospun 
onto the flat or patterned silicone substrates. To the best of our knowledge this level of 
fusion was not previously reported in the literature. Initial fiber-fiber contact during 
electrospinning can result in fusion due to residual solvent in the polymer fibers that 
permits chain entanglement. Therefore, the fiber bundling was attributed to PEsU fiber 
attraction which resulted in fiber contact along the full length of the fiber and subsequent 
fusion. In contrast, the PEUU fibers exhibited no discernable pattern or fiber bundling 
when electrospun onto patterned silicone substrates, Figure A.3A, and indicates a 
previously unobserved material-specific effect on fiber deposition. The PEsU has 
numerous polar carbonyls in its structure, Figure A.1, thus creating multiple dipoles 
within the polymer chain. When in the presence of an electric field, polar molecules 
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align in the direction of the field leading with the positive ends.
188
 It may then be 
extrapolated that while traveling to the collector, PEsU fibers align based on the 
direction of the applied electric field. Upon reaching the collector, the dipoles within the 
PEsU molecules will have their positive ends towards the face of the collector and the 
negative ends away from the collector thus giving the collector a partial negative charge. 
This effect is heightened at the raised features of the silicone substrate due to the 
enhanced electric field at these points, as described above. New fibers are then attracted 
to these fibers because the partial negative ends of the carbonyl groups in the deposited 
fibers attract the partial positive ends in the new fibers. Electrospun fiber deposition over 
time (1, 5, 10, 20, 40 and 60 minutes) was characterized to investigate the effect of 
charge accumulation on fiber patterning. Fiber patterning and fusion occurred as early as 
1 minute and continued without observable difference throughout the 2 hour spinning 
process (data not shown). We hypothesize that initially the topography dictates fiber 
alignment and fiber attraction resulted in continued fiber patterning and fusion. It is 
necessary here to address the fact that non-polar and low polarity molecules will also 
slightly align themselves along the direction of the electric field;
188
 however, this was 
insufficient to yield patterning of the PEUU under the conditions used in this study. 
Generation of a bimodal distribution of fiber diameters may be of great utility in the 
fabrication of tissue engineered scaffolds to modulate mechanical properties, 
degradation rates, and pore sizes. For example, large fibers would be expected to 
degrade slower and thus maintain structural support of the scaffold while rapid 
degradation of the smaller fibers would increase pore size and enhance cell infiltration. 
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A.4 Conclusions 
In summary, we have demonstrated a novel technique to control the deposition 
pattern of electrospun PEsU fibers. The results from this study indicate that a patterned 
insulating collector substrate can be used to control the selective deposition of 
electrospun fibers, this patterning effect is material specific, and that fusion due to fiber 
attraction results in a bimodal distribution of fiber diameters. This method can be used to 
control selective fiber deposition with broad pattern dimensions (50-500 µm) over a 
large area. Patterning was observed as early as 5 minutes and continued throughout fiber 
deposition (up to 2 hours) indicating that thick mats that retain the desired pattern are 
feasible. The combination of ease of use, low cost, tunability, and generation of 
relatively large fiber mats available with this technique greatly expands the utility of 
patterned electrospun scaffolds in tissue engineering. Further investigation of the effect 
of fiber patterning on mechanical properties, degradation rate, and cellular alignment is 
currently in progress.  
 
 
